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Abstract
We have characterized the biological functions of the chromatin remodeling protein Bptf (Bromodomain PHD-finger
Transcription Factor), the largest subunit of NURF (Nucleosome Remodeling Factor) in a mammal. Bptf mutants manifest
growth defects at the post-implantation stage and are reabsorbed by E8.5. Histological analyses of lineage markers show
that Bptf
2/2 embryos implant but fail to establish a functional distal visceral endoderm. Microarray analysis at early stages of
differentiation has identified Bptf-dependent gene targets including homeobox transcriptions factors and genes essential
for the development of ectoderm, mesoderm, and both definitive and visceral endoderm. Differentiation of Bptf
2/2
embryonic stem cell lines into embryoid bodies revealed its requirement for development of mesoderm, endoderm, and
ectoderm tissue lineages, and uncovered many genes whose activation or repression are Bptf-dependent. We also provide
functional and physical links between the Bptf-containing NURF complex and the Smad transcription factors. These results
suggest that Bptf may co-regulate some gene targets of this pathway, which is essential for establishment of the visceral
endoderm. We conclude that Bptf likely regulates genes and signaling pathways essential for the development of key
tissues of the early mouse embryo.
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Introduction
The packaging of eukaryotic DNA into chromatin provides a
general mechanism for the modulation of gene activity and DNA
metabolism through alterations of chromatin architecture. The
structure and composition of chromatin can be altered by a
number of distinct pathways, including post-translational modifi-
cation of histones, ATP-dependent remodeling of nucleosomes,
and incorporation of histone variants [1–3]. ATP-dependent
chromatin remodeling is catalyzed by the large and conserved
SWI/SNF super family of multi-subunit chromatin remodeling
enzymes that are classified into four major subfamilies (SWI/SNF,
ISWI, CHD, and INO80), and distinguished by the common
presence of a SWI2/SNF2-related catalytic ATPase subunit [4,5].
The mammalian ISWI chromatin remodeling complexes
contain either one of two related ISWI ATPases, Snf2l and Snf2h
[6,7]. The Snf2l ATPase is contained in two assemblies–NURF
(Nucleosome Remodeling Factor), which is dedicated to the
regulation of transcription, and the recently reported CERF [8,9].
NURF is the founding member of the ISWI family of chromatin
remodeling complexes, and was originally characterized in
Drosophila [10]. Purified Drosophila NURF catalyzes ATP-
dependent nucleosome sliding and promotes transcription from
chromatin templates in vitro [9]. As shown by whole genome
expression studies of mutants, NURF positively or negatively
regulates transcription of several hundred Drosophila genes in vivo,
including many genes important for fly development [11]. This is
likely accomplished through recruitment of NURF301, the largest
NURF subunit, by gene-specific transcription factors [11–13], and
binding of a PHD finger of NURF301 to tri-methylated lysine 4 on
histone H3 [14]. Human NURF contains the orthologs of three of
four Drosophila NURF components–BPTF (Bromodomain PHD-
finger Transcription Factor), the mammalian counterpart of
NURF301, SNF2L (the ISWI ATPase) and RbAp46/48, a WD-
40 repeat histone-binding protein found in several chromatin-
related protein complexes [15]. Biochemical studies of human
NURF have shown that it has similar properties to its Drosophila
counterpart [15].
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mammalian chromatin remodeling complexes have been revealed
by studies of mouse mutants for the catalytic ATPase. Mutations in
Brg1, Brm, Chd4, Chd2, p400 and Etl1 have been shown to be
required for proper embryonic development, hematopoiesis or
postnatal survival [16–22]. A mutant for the Snf2h, one of the two
murine ISWI ATPases, revealed severe proliferation defects in the
early embryo, resulting in a peri-implantation lethal phenotype
[23]. Given the presence of Snf2h in multiple chromatin
remodeling complexes, the assignment of biological phenotypes
to different enzyme complexes can be problematic [6,7].
By analysis of mutations of unique subunits it is possible to
identify the biological functions of different Snf2h-containing
complexes. This has been accomplished for the Drosophila ISWI
complexes. Studies of mutants for Drosophila NURF301, which is
exclusive to the NURF complex [12], have revealed a late larval-
lethal phenotype and mis-expression of homeotic selector genes
and genes involved in the response to heat stress, cytokine and
steroid hormone signals [11,13]. These phenotypes do not overlap
with those observed for mutants for Drosophila ACF1 (a
component of the ISWI-containing complexes ACF and CHRAC)
which are impaired in the establishment and/or maintenance of
transcriptional silencing in pericentric heterochromatin and in
repression by Polycomb-group genes [24].
To elucidate the biological roles of Bptf-containing complexes
we have generated embryonic stem cell and mouse mutants for
Bptf [15]. Our studies show that Bptf mutant phenotypes begin to
manifest just after implantation stage, and mutant embryos are
completely reabsorbed by embryonic day (E) 8.5. Genetic and
molecular analysis in embryonic stem cells and the mouse suggest
a role for Bptf in the development of visceral endoderm (VE) of the
early mammalian embryo. We propose that Bptf is required for
the development of the VE, and more importantly the distal
visceral endoderm (DVE), in part through regulating cellular
proliferation, the expression of homeobox-containing transcription
factors and pathways regulated by the Smad transcription factors,
a major conduit for cell signaling in development. These findings
suggest a model in which the activities of Bptf-containing
complexes, likely the NURF remodeling complex, regulate cell
proliferation and embryonic development and therefore are
essential in the post-implantation embryo.
Results/Discussion
Characterization of Gene-Trap and Conditional Alleles of
Bptf
BPTF, the mammalian ortholog of Drosophila NURF301, is a
large, multi-domain protein that is apparently exclusive to the
mammalian NURF complex (Figure S1A) [12,15,25]. An initial
characterization of Bptf showed it to be nuclear in the P19
embryonic carcinoma cell line and can exist in at least two
electrophoretic variants, which we termed Bptf-H and Bptf-L
(Figure S1B, Figure S1C). As previously reported, Bptf is highly
expressed in testis, spleen, brain and to a lesser extent in kidney by
Western blotting (Figure S1D). Interestingly Bptf is highly
expressed during embryonic development, and expression sub-
stantially declines upon birth (Figure S1E). The high levels of Bptf
expression in the mouse embryo suggest it may have essential
functions during embryonic development.
To elucidate the biological functions of mammalian Bptf during
mammalian embryonic development we generated two mutant
mouse lines. One line, designated as Bptf
XG023, was derived from an
ES cell line carrying an in-frame gene-trap vector insertion between
exons 15 and 16 of Bptf (Figure S2A, Figure S2B, S2C, S2D, S2E,
S2F) (XG023; http://www.genetrap.org/) [26]. We identified the
precise junction of the insertion site of the gene trap by DNA
sequence analysis of the corresponding PCR products, and
confirmed by RT-PCR that trapping of Bptf mRNA into vector
sequences leads to loss of RNA splicing between exons 15 and 16,
and reduced expression of Bptf sequences 39 to the insertion site
(Figure S3A, Figure S3B). In addition, we confirmed by 59-RACE
that the insertion resulted in an in-frame fusion between Bptf and b-
galactosidase-neomycin phosphotransferase (b-Geo) sequences of the gene-
trap vector. (Figure S3C). Consistent with previous findings,
Northern blotting of adult tissue RNA showed that both wild-type
Bptf and the Bptf–b-Geo fusion alleles are specifically expressed at
high levels in the testis and at moderate levels in the lung, spleen,
and brain (Figure S3D) [25]. These identical RNA expression
patterns initially suggest that b-galactosidase is a faithful reporter of
Bptf expression in adult tissues. These results indicate that the
Bptf
XG023 mutation creates a truncated Bptf–b-Geo fusion carrying
the N-terminal 1978 residues of the 2903-residue Bptf open reading
frame, which eliminates the conserved glutamine rich region, PHD
finger, and bromo-domains.
The second line, designated as Bptf
DExon2, was generated by
targeting loxP sites flanking exon 2 of Bptf (Figure S2A, Figure
S2G, Figure S2H, Figure S2I, Figure S2J, Figure S2K, Figure
S2L, Figure S2M, Figure S2N). The expression of the Bptf
DExon2
allele was assessed by RT-PCR with the use of primer sets which
amplify sequences on the 39 end of the Bptf transcript. We found
that the Bptf
DExon2 allele slightly decreases expression of Bptf at the
RNA level (Figure S4A). However, amplification and sequencing
of the Bptf
DExon2 mRNA from exons 1 to 8 shows an out-of-frame
mutant mRNA, indicating that Bptf
DExon2 behaves as a loss-of-
function allele (Figure S4B, Figure S4C).
Post-Implantation Phenotypes of Bptf Mutant Embryos
We intercrossed heterozygous mice to determine the biological
function of Bptf during mouse development. With 210 mice
Author Summary
While the chromatin of eukaryotes provides an efficient
means to compact large amounts of DNA into a small
nucleus, it renders the DNA relatively inaccessible. ATP-
dependent chromatin remodeling complexes mobilize
nucleosomes and provide a means to gain access to
DNA in chromatin. While the biochemical functions of
chromatin remodeling complexes is well-characterized,
less is known of their biological functions. In this
manuscript, we elucidate the biological functions of Bptf,
a subunit of the NURF chromatin remodeling complex. Our
studies show that Bptf is required for the establishment of
the anterior–posterior axis of the mouse embryo during
the earliest stages of development. To understand its
functions in tissue differentiation, we generated and
characterized Bptf-mutant ES cells. Mutant embryonic
stem cells show significant defects in the differentiation
of ectoderm, endoderm, and mesoderm. Genome-wide
analysis of gene expression defects during differentiation
has identified many Bptf-dependent pathways including
key regulators of ectoderm, endoderm, and mesoderm
differentiation. Moreover, we have identified critical
functions for Bptf during the TGFb/Smad-induced expres-
sion of visceral endoderm and mesoderm markers, an
important signaling pathway in the early embryo. These
results suggest that chromatin remodeling by Bptf
regulates key signaling pathways in the early mouse
embryo.
Bptf and Development of Mouse Embryo
PLoS Genetics | www.plosgenetics.org 2 October 2008 | Volume 4 | Issue 10 | e1000241genotyped for the Bptf
XG023 allele and 75 mice for the Bptf
DExon2
allele, we did not find any surviving homozygous mice at weaning,
indicating that Bptf is required for mouse development. An analysis
of E6.5 to E18.5 progeny derived from heterozygous intercrosses
confirmed that the homozygous mutant phenotype is embryonic-
lethal between E7.5 to E8.5, with 100% penetrance (Table S1).
To identify defects in the embryonic development of Bptf
XG023
and Bptf
DExon2 homozygotes, we performed whole mount exami-
nations of mutant embryos. Growth defects increasing in severity
from E5.5 to E7.5 were observed (Figure 1A) (Figure S5A).
Dissections conducted at E8.5 and E9.5 were uninformative,
because a majority of the embryos had been completely
reabsorbed (data not shown). We crossed Bptf
XG023 and Bptf
DExon2
heterozygous mice to generate the trans-heterozygous Bptf
XG023/
Bptf
DExon2 embryos. The trans-heterozygote recapitulated the
growth defects of the Bptf
XG023 and Bptf
DExon2 homozygotes,
indicating that the two mutations are functionally equivalent
(Figure S5B). To determine whether the developmental defects
originated before implantation, we harvested E3.5 blastocysts and
performed blastocyst outgrowth assays. We observed normal E3.5
homozygous Bptf
XG023 and Bptf
DExon2 blastocysts and normal
outgrowths from the blastocysts after tissue culture for 5 days,
suggesting that either Bptf is not essential for pre-implantation
development or that the maternal Bptf protein or mRNA can
mask pre-implantation phenotypes (Figure S6). The masking of
pre-implantation phenotypes by maternal Bptf is possible because
it is highly expressed in oocytes [27,28].
To further investigate the basis of the early embryonic lethal
phenotype, we performed a histological analysis of Bptf
XG023 mutant
embryos at E5.5, E6.5 and E7.5. Mid-sagittal sections of E5.5, E6.5
and E7.5 embryos stained with hematoxylin and eosin (H&E) showed
a distinct proximal-distal (P-D) axis and the development of visceral
endoderm but a significant decrease in size of the embryonic and
extra-embryonic tissues. This was particularly evident in the
embryonic ectoderm at E6.5 and E7.5 (Figure 1B). By E6.5, mutant
embryos showed clear developmental defects. Although there was a
clear boundary between extra embryonic and embryonic tissues, the
absence of a primitive streak and any discernable mesoderm suggests
that the anterior-posterior (A-P) axis did not form (Figure 1B).
A reduction in cell number can be a consequence of decreased
cell proliferation, increased cell death (apoptosis), or a combination
of both processes. To ascertain the extent of programmed cell
death, we performed TUNEL assays on E5.5, E.6.5 and E7.5
homozygotes and found no increased numbers of apoptotic cells
when compared to controls (Figure 1B). As a measure of cell
proliferation we monitored phosphorylated histone H3 levels in
the conceptus by immuno-histochemistry (Figure 1B). E5.5, E6.5
and E7.5 homozygotes showed ,40–50% decrease in phosphor-
ylated histone H3 levels indicating that a decrease in cellular
proliferation may contribute to the mutant phenotype (Figure S7).
Figure 1. Bptf mutants manifest early embryonic growth defects. (A) Wild type (+/+), heterozygous (+/2), and homozygous (2/2)Bptf
XG023
embryos at E5.5, E6.5, and E7.5 were removed from their decedua and genotyped using the PCR based method. Reduced growth rates are evident in
the homozygous Bptf
XG023 embryos as early as E5.5. (B) Hematoxylin and eosin (H&E) staining of E5.5, E6.5, and E7.5 mutant embryos show reduced
growth of both embryonic and extra-embryonic tissues, the presence of visceral endoderm, and an absence of anterior–posterior asymmetry when
compared to controls. Bptf mutant embryos were stained for phosphorylated histone H3, a marker of cell mitosis. Mutant embryos at E5.5, E6.5, and
E7.5 have significantly reduced staining when compared to controls, suggesting that they have reduced cellular proliferation. Bptf-mutant embryos
were stained for apoptotic cells using the TUNEL assay. Mutant embryos at E5.5, E6.5, and E7.5 do not have any positive staining by TUNEL when
compared to controls, suggesting that they are not apoptotic. Scale Bars: E5.5 and E6.5 embryos=50 mm, E7.5 embryos=100 mm. Abbreviations: ve,
visceral endoderm; ee, embryonic ectoderm; m, mesoderm; xe, extra-embryonic ectoderm; xve, extra-embryonic visceral endoderm.
doi:10.1371/journal.pgen.1000241.g001
Bptf and Development of Mouse Embryo
PLoS Genetics | www.plosgenetics.org 3 October 2008 | Volume 4 | Issue 10 | e1000241Bptf Mutants Fail To Develop a Functional Distal Visceral
Endoderm
Subsequent to implantation of the mouse blastocyst there is
rapid proliferation of the egg cylinder, which consists of three cell
types: the more proximal extra-embryonic ectoderm, the more
distal embryonic ectoderm or epiblast, and an outer layer of
visceral endoderm [29]. The visceral endoderm originates from
the primitive endoderm, a layer of cells organized at E4.5, which is
composed of cells from the ICM of the E3.5 blastocyst expressing
Gata6 but not Nanog [30]. At ,E5.5, a specialized cluster of
endoderm cells, the DVE, arises at the distal tip of the embryo.
DVE cells migrate toward the prospective anterior, to form the
anterior visceral endoderm (AVE). DVE/AVE cells secrete
molecules such as cerberus (Cer1) and Lefty1, antagonists of the
Transforming Growth Factor b (TGFb)-related protein Nodal
[29]. These antagonists restrict the activity of Nodal to the
posterior pole of the embryo at E6.0 [31]. The primitive streak
forms at E6.5, indicating that gastrulation has begun, and gives
rise to the mesoderm and definitive endoderm germ layers [29].
As a first step in the molecular analysis of Bptf in embryonic
development we examined the expression of Bptf using in situ RNA
hybridization. We observed expression in the inner cell mass
(ICM) and primitive endoderm at E4.5 and all embryonic tissues
at E5.5 and E6.5. Interestingly we do not observe Bptf expression
in the visceral endoderm at E5.5 and E6.5 (Figure 2A). We also
monitored the activity of the b-galactosidase moiety of the Bptf–b-
Geo fusion protein in heterozygous mice. Consistent with our in
situ analysis a histochemical analysis of whole mounts showed that
Bptf–b-Geo is expressed in the embryo proper at E5.5, E6.5 and
E7.5 (Figure S8A, S8B, S8C, S8D, S8E, S8F, S8G). Further
analysis of histological sections revealed that Bptf–b-Geo expression
at E7.5 is primarily confined to the embryonic ectoderm, with
reduced levels in mesoderm and no expression in the visceral
endoderm (Figure S8A9, Figure S8B9). At subsequent stages, from
E7.5 to E13.5, histochemical analysis of whole mounts showed
widespread Bptf–b-Geo expression in the developing embryo
(Figure S9A, Figure S9B, S9C, S9D, S9E, S9F). This temporal
correlation between the earliest stages of Bptf expression and the
stages when the mutant phenotype is revealed, suggests that there
could be an essential requirement for Bptf as early as E4.5.
Our histological analysis suggests that Bptf mutants are defective
in establishing an A-P axis. Apparent defects in A-P axis can be
due to defects in the establishment or migration of the DVE [29].
To monitor the development of the DVE and its transition to the
AVE, we analyzed the markers Otx2, Lefty1, Cer1, Hesx1, Hex1,
Gata6, Nanog and Nodal by in situ hybridization in E4.5 to E6.5
mutant embryos [32–37].
An analysis of pre-implantation embryos suggested that Bptf
mutants specify a functional primitive endoderm and ICM. The
primitive endoderm of Bptf mutant embryos was found to express
the primitive endoderm markers Gata6, Lefty1, and Hex1 at
comparable levels to wild type controls (Figure 3B). The expression
of these markers suggests that Bptf mutants are not defective in the
differentiation of the primitive endoderm, the precursor of the
visceral endoderm of E5.5 and later stage embryos. Consistent
with a functional ICM, we observed normal expression of the
pluripotency marker Nanog in Bptf mutants compared to controls
(Figure 2B). Taken together, these results indicate that Bptf is not
required for the specification of the primitive endoderm and the
ICM in E4.5 embryos.
To assess the specification of the VE and DVE, we monitored
the expression of Cer1, Hex1, Gata6, and Nodal in E5.5 Bptf mutant
embryos. We observed that the markers Cer1, Hex1 are
significantly reduced in Bptf mutants relative to the wild type
controls (Figure 2B). The absence of expression of these markers
Figure 2. Bptf mutants are defective in the expression of distal
visceral endoderm markers. (A) Wild type embryos were stained in
whole mount for Bptf mRNA by in situ RNA hybridization at E4.5, E5.5,
and E6.5. Bptf is expressed in the inner cell mass and primitive
endoderm at E4.5 and in the embryonic and extra-embryonic tissues in
E5.5 and E6.5 embryos. Abbreviations: ve, visceral endoderm; ee,
embryonic ectoderm; xe, extra-embryonic ectoderm; DVE, distal visceral
endoderm. (B) Whole mount in situ RNA hybridization analysis of wild
type and mutant E4.5 and E5.5 embryos for Nanog, Gata6, Lefty1, Cer1,
Hex1, and Nodal expression. At E4.5, Bptf mutant embryos show
expression of Nanog, Gata6, Lefty1, and Hex1, suggesting that the
primitive endoderm and inner cell mass is present in Bptf mutants.
Mutant E5.5 embryos are defective in the expression of DVE markers
Cer1 and Hex1, suggesting that mutants cannot form the DVE.
Interestingly, the general visceral endoderm marker GATA6 is not
expressed in the VE but rather in the embryonic ectoderm at E5.5.
doi:10.1371/journal.pgen.1000241.g002
Figure 3. Analysis of Bptf knockout mouse embryonic stem
cells shows severe defects in gene expression during embryoid
differentiation. Relative expression of developmental markers during
an embryoid body differentiation time course. The expression of many
markers of the ectoderm (A), mesoderm (B), and endoderm (C) tissue
lineages were severely defective in Bptf mutants during the differen-
tiation time course.
doi:10.1371/journal.pgen.1000241.g003
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Interestingly Gata6 expression, normally expressed only in the VE
at E5.5 and E6.5, is absent in the VE but present in the epiblast in
mutants at E5.5 (Figure 2B). This suggests that Bptf could also have
roles in specifying the VE as well as the DVE. A key regulator of
DVE specification is Nodal. Nodal expression is found as early as
E4.5 but is not significantly expressed in the epiblast and VE until
implantation is well underway at E5.0 [36,38]. In E5.5 Bptf mutant
embryos we observe normal expression levels of Nodal in the
epiblast and VE as in wild type embryos (Figure S10A). This E5.5
pattern of Nodal expression continues into E6.5 in Bptf mutant
embryos (Figure S10B).
To examine the development of the AVE we monitored the
expression of Cer1, Otx2, Hesx1, Lefty1 and Hex1 in E6.5 Bptf
mutant embryos. Otx2 expression is required for the migration of
the DVE to establish the AVE. We observed lower expression of
Otx2 in the epiblast of Bptf mutant embryos relative to there wild
type controls (Figure S11A). As expected we did not observe
expression of AVE markers Cer1, Hesx1, Lefty1 and Hex1 in Bptf
mutant embryos (Figure S11A). Combined with our analysis of
E5.5 embryos our results strongly suggest that Bptf is required for
the speciation of the DVE and the AVE.
Since Bptf mutant embryos are unable to form a functional DVE
and AVE, we anticipated that they should be defective in specifying
the primitive streak and differentiating mesoderm and definitive
endoderm. Several critical transcription factors and signaling
molecules such as T, Lhx1, Fgf8, Gsc, Foxa2, Nodal, and Cripto (Tdgf1)
serve as effective markers for development of the primitive streak in
the gastrulating embryo [34,39–42]. Our analyses revealed that T,
Lhx1, Fgf8, Gsc, and Foxa2wereundetectable at E6.5,and inthe case
of T, Fgf8 but not Lhx1, were delocalized in expression at E7.5
(Figure S11A, Figure S11B). The absence of expression of primitive
streak markers at E6.5 confirms our histological analyses, and
further supports the observation that gastrulation and mesoderm
formation do not occur in Bptf mutants. Interestingly, the
delocalized Nodal and Cripto expression patterns observed in the
Bptf mutants at E6.5 are highly reminiscent of their expression
patterns prior to the establishment of the DVE (Figure 2B) (Figure
S11A)(Figure S10A,FigureS11B)[34,39].Takentogether,thedata
suggests that Bptf mutant embryos arrest at a stage prior to DVE
formation (,E5.5).
Recent models propose that the extra-embryonic ectoderm
supports the growth of the embryo and is a source of signals for A-P
axis establishment [29]. To address whether the developmental
defects of Bptf mutants are caused by defective extra-embryonic
ectoderm or by a lack of appropriate growth signals in the epiblast,
we monitored the expression of the extra embryonic ectoderm
(Bmp4, Erbb2, Fgfr2), trophectoderm (Mash2), angiogenesis (Vegf,
Flk1) and a cell cycle regulator (JunB) markers [43–47]. We find
Bmp4, Mash2, Erbb2, and Fgfr2 to be expressed normally in the
mutant embryos at E6.5 and E7.5 (Figure S11A, Figure S11B). This
suggests that the growth defects observed in Bptf embryos are not
due to gross defects in the specification the extra-embryonic tissues.
We also observe little to no expression of the angiogenesis markers
Vegf and Flk1 in the extra-embryonic tissues at E7.5 (Figure S11B).
However, expression of the cell cycle regulator JunB is increased in
mutant embryonic ectoderm when compared to wild-type controls
(Figure S11A). JunB is a member of the Ap-1 family of transcription
factors which acts as a negative regulator of the cell cycle [48]. This
up-regulation of JunB is consistent with our observations that Bptf
mutants have reduced cellular proliferation (Figure 1B) (Figure S7).
In summary, our analysis of lineage markers by in situ RNA
hybridization has revealed an essential role for Bptf in specifying
the VE and the DVE of the E5.5 post implantation embryo. These
defects likely lead to the observed absence of an AVE and
primitive streak in E6.5 embryos. The absence of these
developmental organizers arrests the growth of the embryo prior
to gastrulation and is likely a major cause of the early embryonic
lethal phenotype of Bptf mutant embryos.
Bptf Is Required for Embryonic Stem Cell Differentiation
To further explore the role of Bptf in cell differentiation we
generated Bptf knockout mouse ES cells and examined their
development in vitro and in vivo. By gene targeting and transient
Cre expression we were able to generate eight independent
homozygous Bptf
DExon2 knockout ES cell lines with a euploid
karyotype (Figure S12A). We observed varying degrees of reduced
Bptf transcript levels by Northern blotting in mutant cell lines
compared to that of wild type controls (Figure S12B). An analysis
of Bptf
DExon2 mRNA from exons 1 to 8 in wild type and knockout
cell lines shows the message to be out of frame resulting in no
observable protein in the knockout cell lines (Figure S12C, Figure
S12D) (data not shown).
To address the possibility the Bptf is essential for cell viability
and proliferation we measured the doubling time of knockout Bptf
ES and MEF cell lines (Figure S13). Both the Bptf knockout ES and
MEF cell lines were viable but exhibited slightly reduced cellular
proliferation (Figure S14). These results show that Bptf is not
required for cell viability and is only marginally required for
cellular proliferation.
Wemeasuredthedifferentiation potentialofthe BptfknockoutES
cells in vitro as embryoid bodies and in vivo as teratomas. Bptf wild
type and two independent knockout cell lines were subcutaneously
injected into NOD/SCID mice and allowed to form teratomas over
8 weeks. Wild type ES cells formed teratomas in 8/11injected mice.
Bptf knockout lines did not form any observable tumors in 10
injections (data not shown). This study demonstrated that Bptf is
essential for one or more biological processes including cell viability,
proliferation or differentiation in the animal.
We next utilized an embryoid body analysis to monitor
differentiation in Bptf knockout cell lines to ectoderm, mesoderm
and endoderm cell lineages. Analysis of the mutant embryoidbodies
showed little evidence of apoptosisby TUNEL, and similar densities
of PCNA and phosphorylated histone H3 positive cells (Figure
S15A). We did observe that Bptf knockout embryoid bodies were
slightly smaller in size and did not form any observable endoderm
(Figure S15B, Figure S15C). These results indicate that Bptf is not
necessary for cellular survival or proliferation under conditions of
embryoid body differentiation but is essential for differentiation of
endoderm and possibly other advanced tissue lineages.
To investigate the differentiation defects of Bptf knockout embryoid
bodies at a molecular level we monitored the transcription of well
documented markers of endoderm, mesoderm and ectoderm
differentiation (Figure 3A–3C). We observed minimal Bptf depen-
dence for the primitive ectoderm markers FGF5 and Otx2(Figure3A).
However, we did observe significant defects in Nestin transcription, a
marker of neural stem cell progenitors derived from the primitive
ectoderm (Figure 3A). These results indicate that primitive ectoderm
lineages are less dependent on Bptf than the more differentiated
lineages. As anticipated we observed severe defects in the expression
of mesoderm and endoderm markers during the differentiation time
course. We observed little to no activation of mesoderm markers T,
FGF8, Evx1, Wnt3,a n dGsc which are significantly activated in wild
type cultures by day 5. (Figure 3B). Similarly, endoderm markers
Sox17, Cer1, Hnf4a, and Foxa2 show severe expression defects in Bptf
mutant embryoid bodies compared to controls (Figure 3C). In
contrast to the large differences in expression of mesoderm and
endoderm markers we observed less than two fold changes in
Bptf and Development of Mouse Embryo
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exception of Cyclin D1 (Figure S16A, Figure S16B). These defects in
transcription and differentiation were rescued for two independent
knockout lines by retargeting exon 2 to the Bptf
DExon2 locus using the
targeting vector. Our ability to rescue the expression defects of T,Gsc,
Sox17 and Cer suggest that the observed phenotypes are due to Bptf
mutation (Figure S17A, Figure S17B, Figure S17C) (data not shown).
Taken together these results suggest that Bptf is essential for the
formationofmesoderm,endodermandmoredifferentiatedectoderm
lineages in the embryoid body.
We chose a microarray approach to investigate any differen-
tiation defects of Bptf knockout ES cells in undifferentiated and
early differentiation states. Differentiation was induced by LIF
withdrawal (LIF2) or retinoic acid (RA) for three days before
harvesting RNA. A comparison of Bptf-dependent genes by Venn
diagram and manual clustering identifies six categories; those
being affected under only one of the growth conditions (LIF+,
LIF2 or RA Regulation), those being affected in all three
conditions (Constitutive Regulation), a class of genes which were
regulated in the same direction in two of three conditions
(Complex Regulation) and genes with mixed dependence (Mixed
Regulation) (Figure 4A and 4B) (Dataset S1).
From our microarray analysis we observed large changes in
gene expression under conditions of maintained pluripotency
(LIF+) and particularly under conditions of differentiation (LIF2
and RA) (Figure 4A and 4B). As expected many of the essential
markers of early embryonic tissue differentiation that are
dependent on Bptf in embryos are also Bptf-dependent in ES cells
(Figure 4C). These markers include; pluripotency regulators Sox2,
c-Myc, Nanog, visceral endoderm markers Lefty1, Cer1, Hex1, Foxa2
and the primitive streak markers Gsc, Lhx1, Wnt3, Fgf8, T
(Figure 4C). These results reinforce the view that Bptf regulates
the development of ectoderm, endoderm and mesoderm in both
the early embryo and in ES cells.
A gene ontology (GO) analysis of Bptf-dependent expression
datasets revealed an over representation of genes with ‘‘transcrip-
tion factor activity’’, genes involved in the biological processes of
‘‘development’’ and ‘‘morphogenesis’’ and the cellular processes of
‘‘cell death’’ and ‘‘cell proliferation’’ (Figure S18). Notable gene
clusters include the consistent activation of genes correlated with
‘‘nervous system development’’ in all datasets, the repression of
MHC I and II receptors during LIF2differentiation, the
activation of genes correlated with ‘‘cytoskeletal components’’
during RA differentiation (Figure S18). In addition, we observed a
striking over-representation of homeobox transcription factors
within the ‘‘transcription factor activity’’ annotation. The
homeobox-containing genes were almost exclusively up-regulated
in each of the expression categories, and in some cases include
almost the entire Hox gene cluster, indicating that Bptf is required
for their repression in ES cells (Figure S19A, Figure S19B).
From our analysis we also observed that Bptf-dependent gene
targets are more likely to be actively regulated genes, repressed in
the presence of LIF or RA differentiation and conversely activated
under conditions of LIF differentiation (Figure S20A, S20B,
S20C). In support with these observations we observed histone
modifications in Bptf knockout ES cell lines consistent with a
repressed transcriptome under LIF+ growth conditions (Figure
S20D). Interestingly some Bptf-dependent genes cluster together in
the genome (Figure S21).
A Role for Bptf in Distal Visceral Endoderm Formation
A diagnostic defect of Bptf embryos is an inability to form the
DVE. In the absence of the DVE, the AVE cannot form
Figure 4. Analysis of Bptf knockout mouse embryonic stem cells shows severe defects in gene expression during differentiation
with RA and LIF withdrawal. Bptf knockout embryonic stem (ES) cells were induced to differentiate using LIF withdrawal (LIF2) or the addition of
retinoic acid (RA), and gene expression was monitored by microarray. (A) Bptf-dependent genes were defined as genes whose transcription increases
or decreases more than 2-fold in the mutant compared to the wild type with a FDR value of ,0.05. (B) A manual clustering analysis of Bptf-dependent
genes by condition of dependence and expression values. Six expression categories were identified and include genes which are exclusively Bptf-
dependent in LIF2, LIF+, or RA conditions, genes which are dependent in all conditions (constitutive regulation), genes which are dependent in 2
conditions (complex regulation), or genes which vary in direction of misregulation between conditions (mixed regulation). (C) Clustering analysiso f
Bptf-dependent genes important for the development of tissue lineages of the early embryo. Bptf is essential for the proper regulation of many
markers of ectoderm, endoderm, and mesoderm tissue lineages.
doi:10.1371/journal.pgen.1000241.g004
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primitive streak. To further investigate the functions of NURF in
the early embryo we focused on Smad mediated signaling
pathways. Smad mediated signaling pathways are essential for
the formation of the DVE in the embryo and the induction of
mesoderm in differentiating ES cells, two prominent phenotypes of
our in vivo and in vitro studies on Bptf [49,50].
The most prominent ligand activating the Smad transcription
factors in the early embryo is Nodal [51]. Nodal, and the closely
related ligand activin, bind to type I and II TGFb receptors
resulting in the phosphorylation of the type I receptor.
Phosphorylation of the type I receptor activates a kinase domain
which phosphorylates Smads2/3. The phosphorylation of Smad2
or Smad3 transcription factors promotes interactions with Smad4
and triggers the translocation of the Smad complex into the
nucleus [51]. Once in the nucleus, the Smad complex interacts
with DNA sequence specific transcription factors to promote the
regulation of Smad target genes [52].
Accordingly, we monitored the dependence of Smad-responsive
genes on the presence of Bptfin ES cells. EScells readilyresponded to
activin-A as monitored by the phosphorylation of Smad2 (Figure
S22A, Figure S22B). From these experiments we identified a number
of Smad-dependent genes which completely or partially require Bptf
forfullactivation.GenesrequiringBptfforfullactivationincludeCer1,
Gsc and T (Figure 5A). Genes which partially require Bptf include
FGF8, Lefty1 and p21 (Figure 5A) (Figure S23).
To understand the relationship between Bptf and CBP/p300,
known co-activators of the Smad transcription factors, we knocked
down both Bptf and CBP/p300 using siRNA technology and
monitored the activation of the Smad responsive genes Lefty1,
FGF8, Gsc, T, and Cer in ES cells (Figure S22C). As in the Bptf
DExon2
knockout ES cell lines we observed that each of these genes are
dependent on Bptf for full activation (Figure 5B). While some genes
differ in there requirement for Bptf, they are all dependent on
CBP/p300 for activation (Figure 5B). Our results demonstrate that
a genetic knockout and siRNA mediated knockdown of Bptf result
in defects in the activation of Smad responsive genes to varying
degrees. Taken together, these results indicate that Bptf, like CBP/
p300, acts as a co-activator of Smad responsive genes in ES cells.
We also used the embryonic carcinoma cell line P19 to
complement our findings with the Bptf knockout ES cells. We co-
transfected P19 cells with DNA plasmids carrying four minimal
Smad binding elements (SBE), or three activin response elements
(ARE), linked to a core promoter and a luciferase reporter gene.
The ARE and SBE elements were previously found to be the
minimal Smad-responsive elements [53,54]. Under conditions of
Bptf knockdown, we observed a significant reduction in luciferase
activity from both reporters (Figure S24A, Figure S24B).
Figure 5. Bptf is necessary for Smad mediated gene regulation. (A) RT-PCR analysis of known Smad target genes from activin-A induced wild
type (+/+) and Bptf knockout (2/2) embryonic stem (ES) cells shows Cer1, T, Gsc to be dependent, and Fgf8, Lefty1 to be partially dependent on Bptf
for full activation. (B) Like CBP/p300, Bptf regulates Smad-dependent genes in vivo. Bptf or CBP/p300 were knocked down in activin-A induced or
uninduced ES cells. The expression of gene targets was determined by RT-PCR and is expressed as a ratio of induced/uninduced for each knockdown
condition. Lefty1, Fgf8, T, Gsc, and Cer1 require both Bptf and CBP/p300 for full activin-A–dependent gene activation. (C) NURF interacts with the
Smad transcription factors in vitro. Recombinant NURF complex was subjected to GST pull-down assays using resin bound GST, GST-Smads, GST-
Smad fragments, and GST-b-catenin. GST-Smad2 and 3 but not GST and GST-b-catenin controls can specifically pull down the NURF complex. The
GST-Smad2C containing the C-terminal fragment of Smad2 specifically pulls down the NURF complex. The C-terminal domain of Smad2 interacts with
native NURF from crude nuclei extracts. High salt nuclei extracts from ES cells was subjected to GST pull-down assays using resin bound GST and GST-
Smad fragments. The GST-Smad2C containing the C-terminal fragment of Smad2 specifically pulls down the Bptf and Snf2h/l components of the
native NURF complex and the histone acetyl-transferase CBP from nuclei extracts. (D) Chromatin immunoprecipation of Snf2h/l and histone
modifications 3me-K4H3 and 3me-K27H3 at Lefty1 show recruitment of the Snf2h/l subunit to the neural plate specific enhancer (NPE), a region which
contains Smad binding elements, in a Bptf and an activin-A–dependent manner. Snf2h/l ChIP is expressed as a ratio of induced (+activin-A) to
uninduced (2activin A). Histone modifications are shown during induced (+activin-A) conditions for +/+ and 2/2 cells and have been normalized to
a pan histone H3 pulldown. NPE=neural plate specific enhancer, LPE=lateral plate specific enhancer, RSS=right side specific enhancer.
doi:10.1371/journal.pgen.1000241.g005
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combinations of Smads 2,4 with constitutively active TbRI
(ALK5), the type I receptor for the TGFb signaling pathway
(Figure S24C) [55]. Using this system we observed efficient
reduction in the activation of the SBE regulated luciferase reporter
gene with a siRNA to Bptf but not a mock siRNA control (Figure
S24D). We repeated the experiments using multiple unique
siRNAs and measured the transcription of endogenous TGFb
regulated genes. In these experiments we used three individual Bptf
siRNAs which were effective in knocking down protein expression
after 2 days of culture (Figure S24E). We then stimulated the P19
cells with TGF-b1. Like nodal and activin-A, TGF-b1 stimulates
the phosphorylation of Smad 2/3 through the dimerization and
activation of similar type I and II receptors. We similarly observed
a significant reduction of Cer1 and T transcription in Bptf depleted
cells upon Smad2/3 activation with TGF-b1 (Figure S24F). We
also used the human breast cancer cell line MCF10CA1 in similar
assays to determine if BPTF could play a role in Smad signaling in
humans [56]. In these experiments we used BPTF siRNAs which
were effective in knocking down protein expression in MCF10CA1
cells after 2 days of culture (Figure S24G). We then stimulated the
MCF10CA1 cells with TGF-b1 for 1 hour. We observed a
significant reduction of PAI-1 but not SMAD7 induction
suggesting that, as in the mouse, BPTF could regulate a subset
of Smad responsive genes in humans (Figure S24H).
We next investigated whether the interaction between the
BPTF-containing NURF complex and the Smads is direct or
indirect using pull-down assays. Experiments with bacterially
expressed GST-Smad2 or GST-Smad 3 showed an interaction to
a degree between recombinant NURF complex and each of the
Smad transcription factors, but not the GST or GST-bcatenin
controls (Figure 5C). Smad transcription factors are composed of
functional domains at the N-terminus (MH1 domain) and C-
terminus (MH2 domain). The N-terminal+linker and C-terminal
regions of Smad2 were used in similar pulldown experiments. We
observed that recombinant NURF complex interacts specifically
with the MH2 domain of Smad2 (Figure 5C). This interaction was
also observed for the Bptf and Snf2l components of native NURF
complex from crude ES cell nuclear extracts (Figure 5C). We also
confirmed the reported interaction of the C-terminal MH2
domain of the R-Smads with the co-regulator CBP (Figure 5C)
[57]. Hence, our results suggest that NURF, like p300 and CBP
maybe recruited to the promoters of TGFb responsive genes
through direct interactions with the Smad transcription factors.
Our current model proposes that Bptf-containing complexes
like NURF are recruited to the promoter of Smad regulated genes
through direct interactions with the Smad transcription factors. To
test this model, we initiated chromatin immuno-precipitation
(ChIP) experiments to detect the Snf2l component of the NURF
complex at Lefty1. As anticipated, we observed significant
enrichment of Snf2l at the Neural Plate Specific Enhancer
(NPE), a region which contains putative FAST and Smad
transcription actor binding sites, of the Lefty1 promoter [58]. This
enrichment was dependent on activin-A stimulation and on the
presence of Bptf (Figure 5D). Snf2l enrichment correlates with the
presence of the activating histone modification H3K4me3 at the 59
UTR of Lefty1 (Figure 5D). These results are consistent with Bptf
recruitment to the promoter of Lefty1 through the Smad
transcription factors.
Discussion
In this work we report a post-implantation lethal phenotype for
mutations in Bptf, the previously characterized largest subunit of
the NURF chromatin remodeling complex [15]. In the early
embryo Bptf is expressed by E4.5 in the ICM and primitive
endoderm. At later stages of development Bptf is expressed in both
embryonic and extra-embryonic ectoderm by E5.5. Following
gastrulation, Bptf is widely expressed in all germ layers to E13.5.
Bptf expression is essential for early development because
homozygous Bptf mutant embryos are reabsorbed by E8.5. No
overt defects were observed in the mutant E3.5 or E4.5 embryo or
its ability to proliferate in culture, suggesting that Bptf embryos
undergo a normal initial specification and proliferation of the
ICM, primitive endoderm and trophectoderm. However, mutant
embryos exhibit diminished proliferation post-implantation as
shown by defects in size of both extra-embryonic and embryonic
tissues and decreased phosphorylated histone H3 staining. A
histological analysis of mutant embryos at E6.5 and E7.5 revealed
that they develop a VE but do not form a primitive streak or
differentiate mesoderm. To investigate the causes of the defect in
gastrulation, we monitored the expression of key markers prior to
and during gastrulation in the embryo. As anticipated we failed to
observe expression of primitive streak markers T, Foxa2, Gsc, Fgf8
or the posterior localization of Nodal and Cripto expression. Defects
in the expression of primitive streak markers and the delocalized
expression of Nodal and Cripto are likely due to the absence of the
DVE/AVE. Defects in the DVE/AVE were confirmed by
observing significantly reduced expression of the markers Cer1,
Hex1, Lefty1 and Hesx1 in E5.5 and E6.5 embryos. Defects in Gata6
expression at E5.5 suggest that the defects in DVE specification
are accompanied by general defects in VE specification. From
these studies we conclude that a critical function for Bptf during
mammalian development is directly or indirectly to specify the VE
and DVE after implantation.
To identify Bptf-dependent gene targets we employed a
microarray based approach on Bptf knockout ES cells during the
early stages of differentiation and an embryoid body model. We
discovered a role for Bptf in the regulation of gene clusters essential
for development, morphogenesis, nervous system development
and cell death and proliferation. Interestingly many transcription
factors, primarily the homeobox-containing genes, are dependent
on Bptf for their proper repression during undifferentiated and
differentiated states. This dependence is interesting as NURF has
been shown to be a activator of Hox gene transcription in more
differentiated tissues in Drosophila and the mouse [13,15]. As
expected many markers of ectoderm (Nestin, Fgf5), mesoderm (Gsc,
Lhx1, Fgf8, Tbx6, Wnt3) and endoderm (Lefty1, Cer1, Nodal, Hesx1)
cell lineages require Bptf for their expression. These gene targets
corroborate well with those identified from our in vivo studies on
Bptf mutant embryos further supporting the conclusion that Bptf is
essential for the development of ectoderm, mesoderm and
endoderm. This also suggests that our microarray dataset obtained
from ES cells is a reasonable approximation of the expression
defects occurring in Bptf mutant embryos in vivo.
A Model for Bptf Function in Early Mammalian
Development
The functions for Bptf in the early embryo are undoubtedly
complex. Our unbiased analysis of gene targets by microarray
revealed many potentially Bptf-dependent differentiation path-
ways. Most relevant to this study include the regulation of the cell
cycle and the differentiation of mesoderm and endoderm lineages,
specifically the VE and DVE. The underlying cause for these
defects could largely be due to the loss of chromatin associated
complexes like the NURF chromatin remodeling complex. In the
case of NURF the defects could be direct, as a remodeling activity
at the promoter of genes necessary for cellular proliferation and
differentiation, or indirect through the deregulation of master
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scription factors. Moreover the underlying mechanism of Bptf
action as a co-activator of some genes and a co-repressor of others
is unclear. Further studies of nucleosome positioning and
chromatin structure in mutants should clarify these possibilities.
In addition to system-wide defects with Bptf deletion, there could
be specific defects in individual signal transduction pathways
within the embryo or in the ability of the embryo to receive growth
signals from the extra-embryonic tissues or the surrounding
decidua. To identify potential Bptf-dependent signaling pathways
we focused on its role in specifying the DVE. The pre-gastrulation
embryo uses three well-known signaling pathways, the WNT/b-
catenin, FGF/MAPK and Nodal/Smad pathways, to establish A-
P asymmetry [29]. The three pathways can be distinguished by
different A-P phenotypes. In mutants of FGF/MAPK signaling the
epiblast has severe proliferation defects, do not specify primitive
endoderm, are quickly reabsorbed and the blastocysts do not
outgrow when grown in culture [30,44,59,60]. Mutations in the
WNT/b-catenin, but not Nodal/Smad pathways, develop the
DVE and in some cases the AVE [50,61–63]. The ability of the
Bptf embryos to form blastocyst outgrowths, specify the primitive
endoderm, but not form the DVE is reminiscent of mutants in the
Nodal/Smad signaling pathway rather than a defect in FGF/
MAPK or WNT/b-catenin signaling (Table S2).
Because Bptf has been associated with the NURF complex, a
known regulator of transcription, the data suggests that Bptf is
required for the expression of gene targets in the developing VE
and DVE. In support of this hypothesis, we showed that Bptf is
required for the regulation of endogenous promoters and Smad
responsive promoter elements in ES, P19 and MCF10CA1 cells in
tissue culture. Smad-dependent gene targets include those essential
for cell proliferation (p21) and those essential for DVE function
(Cer1, Lefty1) and primitive streak (T, Fgf8, Gsc). Moreover,
pulldown assays showed that components of the NURF complex
have direct interactions with the Smad transcription factors and it
is recruited to the promoters of Smad regulated genes under
conditions of activation. Taken together, our data suggest that Bptf
can directly regulate Smad regulated genes, likely through the
functions of the NURF remodeling complex, via recruitment by
the Smad transcription factors (It is also possible that other as yet
unidentified Bptf-containing complexes distinct from NURF
function in this pathway). To address the possibility that the
effects on the Nodal/Smad pathway are indirect we monitored the
expression of key components of the pathway in embryos. We did
not observe significant changes which could explain the observed
defects in Smad signaling in the early embryo or during embryoid
body differentiation in Bptf mutants (Figure S25).
Consistent with these findings, the ISWI ATPase, a component
of Drosophila NURF, ACF and CHRAC has been reported to be
important for transmitting Dpp/TGFb signals to stem cells in the
Drosophila ovary [64]. However, we wish to emphasize that the Bptf
mutation likely affects many different pathways and biological
processes, each of which may contribute to biological phenotypes.
The challenge for the near future will be to uncover each of the
many functions of Bptf in mammalian chromatin biology.
Materials and Methods
Targeting Vector Construction
The RPCI21 mouse PAC library (MRC Genomic Resource
Center, England) was screened using a random hexamer labeled
probe to Bptf exon 2. Blotting was performed in hybridization bags
using 0.25 M sodium phosphate pH 7.2, 1 mM EDTA, 7% SDS,
at 65uC overnight with rocking. Blots were washed 5 times for
10 min with 0.256SSC, 0.1% SDS at 65uC. Eight positive clones
wereidentifiedusingX-rayfilm as;367-I21,373-D5,402-C16,402-
E15, 426-P15, 540-B9, 625-D23, 582-P16. Clone 367-I21 was
confirmed by Southern blotting using Eco RI and Sal I digests and
Bptf exon2 probe. Genomic sequence for the construction of the
targeting vector was retrieved into bluescript SKII (Stratagene) and
the integration of loxP sites and Neo selectable marker was
performed using recombineering technology described previously
[65]. The sequence of the targeting vector is available upon request.
Targeting Bptf in ES Cells
Linearized vector was electroporated into CJ7 ES cells and 71
individual Neo resistant and HAT resistant clones were isolated
according to previously published procedures [66]. Clones were
screened for successful Bptf targeting using Eco RI, probe 29–31;
Bam HI, probe exon2; and Sca I, probe exon2. 16 of 71 isolates
were found to be correct for a recombination frequency of 22%.
To create heterozygous, conditional homozygous, homozygous
knockout and rescue Bptf ES cell lines we transiently expressed Cre
followed by retargeting. The piCre expression vector was
electroporated into clone 7010 and conversion from Bptf/
Bptf
FloxedNeo to Bptf/BptfD
exon2 was first screened for by PCR then
confirmed by Southern blotting. Three clones were identified
using this strategy, and clone 7004 was used for subsequent
targeting. The wild type allele in the Bptf/BptfD
exon2 from clone
7004 was then retargeted using the Bptf exon 2 targeting vector.
Individual conditional homozygous clones were first screened for
by PCR then confirmed by Southern blotting. Two Bptf
FloxedNeo/
BptfD
exon2 clones were obtained and named H12 and B19. The
piCre expression vector was electroporated into H12 and B19 and
conversion from Bptf
FloxedNeo/BptfD
exon2 to BptfD
exon2/BptfD
exon2 was
first screened for by PCR then confirmed by Southern blotting. A
total of 9 and 5 homozygous knockout clones were obtained from
the H12 and B19 parental lines respectively. The karyotype of the
knockout lines were confirmed using Giemsa staining and lines
with an anuploid karyotype were discarded. ES cells were
maintained on mitomycin C treated primary mouse embryonic
fibroblasts (MEFs) and ES Cell Growth Media (15% FCS (ES Cell
grade, Invitrogen), DMEM, essential amino acids,10 mM mercap-
to-ethanol, 2 mM glutamine, 100 U/ml LIF (Chemicon Interna-
tional), penicillin and streptomycin) throughout. Lines were
passaged off MEFs onto gelatinized plates for 3 passages prior to
any molecular analysis.
Rescue lines were made by retargeting one allele of BptfD
exon2 in
clones Bptf mutant clones P2-G2 and P2-B9. Individual Neo
resistant and HAT resistant clones were selected on mitomycin-C
treated MEF feeder layers in ES Cell Growth Media (15% FCS
(ES Cell grade, Invitrogen), DMEM, essential amino acids,10 mM
mercapto-ethanol, 2 mM glutamine, 100 U/ml LIF (Chemicon
International), penicillin and streptomycin) throughout. Successful
retargeting events were confirmed by Southern analysis as
described below.
Production of Chimera Mice and Animal Husbandry
Clone 7010 was used to make chimera mice as described
previously [66]. Removal of frt-Neo-frt and deletion of LoxP-
exon2-LoxP was accomplished by crossing to mice expressing Tg-
CMV-Flp and Tg-CMV-Cre to Bptf
FloxedNeo to create the Bptf
Floxed
and BptfD
exon2 lines respectively. Individual recombinants were
identified by Southern blotting and maintained by backcrossing to
C57B6/CRL.
Mice used in this study were maintained in a Specific Pathogen
Free environment at the National Institutes of Health at Bethesda
(MD, USA). Mice were maintained on a 12 hr light/dark cycle
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libtium throughout the duration of the study. All experiments and
animal maintenance procedures were approved by the Animal
Care and Use Committee of the National Cancer Institute under
protocol LMCB001 and its modifications.
NCI-Frederick is accredited by AAALAC International and
follows the Public Health Service Policy for the Care and Use of
Laboratory Animals. Animal care was provided in accordance
with the procedures outlined in the Guide for Care and Use of
Laboratory Animals’’ (National Research Council; 1996; National
Academy Press; Washington, D.C.).
Bptf
XG023, Bptf
FloxedNeo, Bptf
Floxed, and BptfD
exon2 embryos on a B6/
129 mixed background have been cryopreserved at the Cryopres-
ervation and Assisted Reproduction Lab, National Cancer
Institute, Frederick (MD, USA) as BPTFXG023, BPTFFloxed-
NEO, BPTFFloxed and BPTFdel-exon2 respectively. These
mouse lines are available to the research community by request.
Southern Blotting Genotyping Procedures
Mice were routinely genotyped by Southern blotting restriction
digested tail DNA. Tail DNA was prepared using standard
procedures [67]. ,10 mg of DNA was digested withthe appropriate
restriction enzyme and resolved by 0.5% agarose gel electrophoresis
for standard electrophoresis or 1.0% agarose using FIGE. DNA was
transferred to Hybond XL (Amersham) using alkaline capillary
transfer crosslinked withUV (Stratalinker) and probed with random
hexamer labeled probes at 65uC using Perfect Hyb Hybridization
Buffer (Sigma). Probes used for blotting were PCR amplified from
pCH110 (Genbank # UO2445) using primers JL510 and JL511 for
Probe B, and from mouse genomic DNA using primers JL299 and
JL300 for Probe A; JL60 and JL61 for probe exon2; JL235 and
JL236 for probe 29–31; JL293 and JL294 for probe 25–26; JL295
and JL296 for probe 20.2–20.7 using Taq polymerase (Invitrogen)
(see Table S3 for primer sequences). Blots were washed twice with
2.06 SSC, 0.1% SDS and twice with 0.56 SSC, 0.1% SDS for
10 min @ 65uC foreach wash. A Phosphoimagerwasused todetect
the hybridization signal.
PCR Genotyping Procedures
Embryos were genotyped using a PCR based strategy. Primers
used for genotyping the Bptf
XG023 line were as follows, Primer A
(JL511), Primer B (JL627), and Primer C (JL631) (see Table S3 for
primer sequences). PCR reactions were performed in 25 ml
volumes with 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 1.5 mM
MgCl2, 0.2 mM each dNTP, 0.2 mM each primer, 1 Unit Taq
Polymerase (Invitrogen). Reactions were heated for 3 min at 94uC,
and then cycled for 35 cycles at 30 sec at 94uC, 30 sec at 65uC,
and 45 sec at 72uC, followed by one cycle for 2 min at 72uC. PCR
products were resolved on 1.5% agarose gels. The genotype of
embryos was confirmed by the presence of a 250 bp Bptf and/or
500 bp Bptf
XG023 bands.
Two different PCR strategies were used for genotyping the
Bptf
Dexon2 line. The primers used in the first strategy are as follows,
Primer A (JL648), Primer B (JL649), and Primer C (JL652) (see
Table S3 for primer sequences). PCR reactions were performed in
25 ml volumes with 20 mM Tris-HCL (pH 8.4), 50 mM KCl,
1.5 mM MgCl2, 0.2 mM each dNTP, 0.2 mM each primer, 1 Unit
Taq Polymerase (Invitrogen). Reactions were heated for 3 min at
94uC, then cycled for 35 cycles at 30 sec at 94uC, 30 sec at 60uC,
and 45 sec at 72uC, followed by one cycle for 2 min at 72uC. PCR
products were resolved on 1.5% agarose gels. The genotype of
embryos was confirmed by the presence of a 250 bp Bptf, 325 bp
Bptf
Floxed and Bptf
FloxedNeo or 550 bp BptfD
exon2 band.
The primers used in the second method are as follows, Primer C
(JL651), Primer E (JL655), and Primer F (JL662) (see Table S3 for
primer sequences). PCR reactions were performed in 25 ml
volumes with 20 mM Tris-HCL (pH 8.4), 50 mM KCl, 1.5 mM
MgCl2, 0.2 mM each dNTP, 0.2 mM each primer, 1 Unit Taq
Polymerase (Invitrogen). Reactions were heated for 3 min at 94uC,
then cycled for 35 cycles at 30 sec at 94uC, 30 sec at 65uC, and
45 sec at 72uC, followed by one cycle for 2 min at 72uC. PCR
products were resolved on 1.5% agarose gels. The genotype of
embryos was confirmed by the presence of a 375 bp Bptf, 475 bp
Bptf
Floxed or 650 bp BptfD
exon2 bands.
To confirm Bptf
XG023 and BptfD
exon2 expression and an out of
frame Bptf mRNA in the Bptf
Dexon2 line we designed primers with
homology to the 39 end and exons 1 through 8 of the Bptf mRNA.
Total RNA from wild type and Bptf
Dexon2 homozygous embryos
was converted to cDNA using superscript II according to
manufacturer’s procedures. Bptf expression was estimated by first
normalizing cDNA to equal concentration with GAPDH amplifi-
cation. Following GAPDH normalization 39Bptf was amplified.
Both GAPDH and Bptf were amplified in the linear range as
follows. Reactions were heated for 10 min at 94uC, then cycled for
22 cycles for GAPDH and 30 cycles for Bptf at 20 sec at 94uC,
20 sec at 60uC, and 30 sec at 72uC. PCR products were resolved
by native PAGE. The exon 1–8 junction was amplified using
primers P3 and JL15 in 25 ml volumes with 20 mM Tris-HCL
(pH 8.4), 50 mM KCl, 1.5 mM MgCl2, 0.2 mM each dNTP,
0.2 mM each primer, 1 Unit Taq Polymerase (Invitrogen) (see
Table S3 for primer sequences). Reactions were heated for 3 min
at 94uC, then cycled for 35 cycles at 30 sec at 94uC, 30 sec at
65uC, and 2 min at 72uC, followed by one cycle for 5 min at
72uC. PCR products were resolved on 1.5% agarose gels. PCR
fragments were cloned using TOPO TA cloning system (Invitro-
gen) and sequenced with Big Dye V3.1 using M13 forward and
reverse primers.
The exact integration site for the Bptf
XG023 insertion allele was
confirmed by sequencing a PCR product generated by amplifying
genomic DNA from a heterozygous mouse tail clipping. The DNA
was amplified using primers JL511 and JL515 (see Table S3 for
primer sequences). Reactions were heated for 3 min at 94uC, then
cycled for 35 cycles at 30 sec at 94uC, 30 sec at 65uC, and 60 sec
at 72uC, followed by one cycle for 2 min at 72uC. A ,1.8 Kb
PCR product was resolved on 1.5% agarose and purified. The
product was sequenced using Big Dye v3.1 using primer JL511 to
obtain Bptf
XG023 junction sequence.
Bptf
XG023 disruption was confirmed by 59 RACE according to
established procedures from Bptf/Bptf
XG023 total testis RNA
according to procedures established by the Bay Genomics Gene
Trap Consortium (http://baygenomics.ucsf.edu/). Two separate
59 RACE reactions were sequenced giving identical results.
Embryo Procedures
Timed pregnancies used to collect embryos were preformed
using standard procedures [67]. Embryonic day 0.5 was recorded
the morning after an observable plug was found. Portions of later
stage E18.5 to E10.5 embryos were genotyped by Southern
blotting and early E9.5 to E3.5 embryos and outgrowths were
genotyped by PCR.
Embryos used for b-galactosidase staining, in situ hybridizations
and phenotypic analysis were dissected from their deciduas in PBS
at room temperature prior to staining/hybridization. Embryos
were stained for b-galactosidase activity or used for in situ
hybridizations using established protocols [67] (T. Yamaguchi,
personal communication). Probes used for in situ RNA hybridiza-
tions were labeled with DIG according to standard procedures
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follows T, Lhx1, GATA6, Lefty1, FGF4, FGF8, HesX1, Hhex, Cripto,
BMP4, Otx2, Nodal, Cer, Foxa2, Erb2, Fgfr2, Mash1, JunB, VEGF and
Flk1. In situ signals were detected using BM Purple AP Substrate
according to manufactures instructions (Roche). Embryos selected
for sectioning were post fixed in 4% PFA overnight at 4uC,
dehydrated in alcohol and embedded in paraffin and sectioned
after b-galactosidase staining. Sectioned embryos were obtained
using standard techniques [67]. Embryos genotyped following b-
galactosidase staining or in situ hybridization were prepared post
staining by digesting the embryo proper overnight at 55uCi n1 0t o
20 ml PBS, 0.1% tween 20, 2 mg/ml PCR grade protenase K
(Roche). Proteinase K was heat inactivated at 100uC for 15 min
and 2 ml was subsequently used for PCR genotyping.
Deciduas used for sectioning were dissected from the uterus in
PBS, washed once with PBS and immersed in 4% PFA buffered
with PBS overnight at 4uC. Deciduas were then dehydrated in an
ethanol series and imbedded in paraffin. Paraffin blocks were
trimmed and sectioned and sections were stained with hematox-
ylin and eosin, TUNEL assay and phosphorylated H3 according
to standard procedures [67].
Embryos used for RT PCR analysis were dissected in DMEM,
25 mM HEPES pH 7.4, 15% FCS, 2 mM glutamine, penicillin
and streptomycin. Embryonic and extra embryonic tissue was
removed from the ectoplacental cone and frozen in dry ice. The
ectoplacental cone was grown ex vivo in DMEM, 15% FCS,
glutamine, penicillin and streptomycin using standard culture
conditions. After 4 days growth extra embryonic cells were
removed from the outgrowth and subjected to PCR genotyping as
described above and qPCR as described below.
Outgrowth assays were preformed on E3.5 blastocysts. E3.5
blastocysts were isolated in 15% FCS, M2, 10 mM mercapto-
ethanol, penicillin and streptomycin using standard procedures.
Blastocysts were then transferred to gelatinized plates containing
15% FCS, M16, 10 mM b-mercaptoethanol, 2 mM glutamine
with penicillin and streptomycin. Outgrowths were cultured under
standard conditions for 5 days and observed for defects. At the end
of the experiment the outgrowths were removed and genotyped by
PCR using conditions above.
Tissue Extraction
Mouse tissues were extracted from 3 month old male mice
sacrificed by CO2 asphixation and immediately frozen in liquid
nitrogen. Tissues were then extracted using TriReagent (Sigma)
according to manufacturers established procedures. RNA precip-
itate was extensively washed in 80% EtOH, re-suspended in
DEPC treated water and stored at 280uC. Protein precipitate was
extensively washed with 0.3 M guanadininum hydrochloride, 95%
ethanol and re-suspended in 8M urea, 1% SDS and stored at
280uC. Protein concentration was determined using the DC
Protein Assay (BioRad) according to manufacturer’s procedures.
mRNA from embryos successfully genotyped as WT or Bptf2/
2 from ectoplacental growth outgrowths was isolated using Quick
Prep Micro mRNA Purification Kit (Amersham).
Northern Blotting
RNA samples were denatured, resolved by formaldehyde
agarose electrophoresis and blotted to Gene Screen (Dupont) by
high salt capillary transfer according to standard procedures. Blots
were probed with random hexamer labeled DNA probes using
Prefect Hyb hybridization solution (Sigma) at 65uC according to
the manufactures procedures. Probes used were the Probe B and
Exon2 probe described above. Blots were washed with four times
with 16SSC for 10 minutes at 65uC. Phosphoimager was used to
detect the hybridization signal.
Western Blotting
Protein samples were diluted in SDS sample buffer and resolved
by PAGE. 50 mg total protein was transferred to PVDF (Biorad)
using 10 mM CAPS, pH 10.5, 15% methanol, 3.5 mM DTT
transfer solution for 17 hours at 20 mA and 20 V limits.
Membranes were blotted with affinity purified anti-Bptf at
1:10000 dilution [14], M2 anti Flag monoclonal antibody at
1:5000 (Sigma), anti Smad2 and Smad2-phos (Cell Signaling
Technologies) 1:1000, anti SNF2H/L (Abcam) 1:5000, anti-CBP
and p300 1:100 (Abcam) overnight at 4uC then anti rabbit or
mouse HRP (Amersham) at 1:20000 dilution for 2 hrs at RT in
PBS with 5% NFDM and 0.1% tween 20 through out.
Histone Western blotting was performed essentially as above.
Protein samples were extracted from ES cells grown on gelatinized
plates in ES cell growth media containing 100 U/ml LIF using
TriReagent according to manufacturer’s procedures (Sigma).
50 mg of total protein was resolved by 15% SDS PAGE and
transferred to PVDF (Biorad) using 12.5 mM Tris, 96 mM glycine
pH 8.3, 20% methanol transfer solution for 1 hour at 200 mA and
25 V limits. Blots were probed with rabbit polyclonal antibodies to
H4 ac-K5, H4 ac-K8, H4 ac-K12 (Serotech), H4 3me-K20, H4
acK16, H3 3me-K9, H3 3me-K27 (Upstate), g-H2AX, H3 3me-
K4, H3 ac-K14, H3 ac-K18 (abcam) at 1:2000 dilutions overnight
at 4uC then anti rabbit HRP (Amersham) at 1:4000 dilution for
1 hrs at RT in PBS with 5% NFDM and 0.1% tween 20 through
out. Detection was preformed using Pico signal ECL according to
manufacturer’s procedures (Pierce).
Tissue Culture Procedures and Luciferase Assays
ES cells were maintained on mitomycin C treated MEFs in ESC
Growth Media (15% FCS (ES Cell grade, Invitrogen), DMEM,
essential amino acids, 10 mM mercapto-ethanol, 2 mM glutamine,
100 U/ml LIF (Chemicon International), penicillin and strepto-
mycin). Culture techniques used were described previously [66].
Lines were passaged 3 times onto gelatinized plates to remove
MEFs prior to experiments.
Growth rates of ES cell lines were obtained on gelatinized plates
in the absence of feeder layers. Cells were plated @ 1.0610
5 in 6
well plates. Cell number was determined every day for 4
consecutive days with changes in ESC Growth media occurring
every day.
Activin-A stimulation of ES cells was performed as follows. ES
cell lines were started on gelatinized plates in ESC Growth Media.
Cultures were then grown for 2 days in ESC Growth Media
without LIF. On the third day, cells were cultured in low serum
ESC Growth Media without LIF (same as ESC Growth Media
except 0.1% FCS is used instead of 15% FCS) in the presence or
absence of 30 ng/ml activin-A (R & D Systems) overnight. Cells
were processed using TriReagent according to manufactures
standard protocol.
p300, CBP siRNA knockdowns were preformed as follows. ES
cells were grown in ES Cell Growth Medium with 100 U/ml LIF
on gelatinized plates. Cells were collected using trypsin and
transfected using an Amaxa Nucleofector device using solution ES
Cell and program A-30 according to manufacturer’s procedures.
2.0610
6 ES cells were transfected with 400 nmoles siRNA duplex
(Darmacon) or a GFP-Max nucleofection control. Post nucleofec-
tion 1.0610
6 cells were plated to each well of a 6 well gelatinized
tissue culture plate. Cells were stimulated with or without Activin-
A in low serum ES Cell growth media as described above. Cells at
specified time points were lysed using TriReagent reagent (Sigma)
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procedures.
MCF10CA1h cells were grown in a 1:1 mixture of DMEM and
Ham’s F12 medium (Gibco) supplemented with 5% horse serum.
Cells were collected using trypsin and transfected using an Amaxa
Nucleofector device using solution V and program T-27 according
to manufacturer’s procedures. 2.0610
6 cells were transfected with
400 nmoles siRNA duplex (Darmacon) or a GFP-Max nucleofec-
tion control. Post nucleofection 1.0610
6 cells were plated to each
well of a 6 well tissue culture plate. Cells were grown for 2 days in
growth media and then serum deprived in 1% FBS, DMEM,
nonessential amino acids, 10 mM b-mercaptoethanol overnight.
Following serum shock cells were incubated with or without 5 ng/
ml TGF-b1 (R&D Systems) for 1 hour. Cells were lysed using
TriReagent reagent (Sigma) and RNA and protein were purified
according to manufacturer’s procedures.
P19 cells were obtained from the ATCC (ATCC Number CRL-
1825). Cells were grown in 10% FBS, DMEM, 2 mM glutamine,
penicillin and streptomycin. Cells were transfected using an
Amaxa Nucleofector device using solution V and program C-20
according to manufacturer’s procedures. 2.0610
6 P19 cells were
transfected with 400 nmoles siRNA duplex (Darmacon) or a GFP-
Max nucleofection control. Post nucleofection 3.0610
5 cells were
plated to 12 well plates. Cells were allowed to grow for two days
then were serum starved for 18 hours in 0.1% FBS, DMEM,
2 mM glutamine, penicillin and streptomycin. Cells were induced
with 5 ng/ml TGF-b1 (R&D Systems) in low serum growth
medium overnight. Cells were lysed using TriReagent reagent
(Sigma) and RNA and protein were purified according to
manufacturer’s procedures.
Luciferase assays were performed in 12 well format by
transfecting 0.6 mg pGL3ti-(SBE)4 or pAR3-Luc, 0.012 mg
pCH110 with or without 0.6 mgT bRI or 0.6 mg Smad 2-HA
and 0.006 mg Smad4-HA, 40.0 pmoles siRNA duplex per well
using Lipofectamine 2000 (Invitrogen). In experiments using TGF-
b1 (R&D Systems) or Activin-A (R&D Systems) cells were allowed
to grow for 48 hours in 10% FBS, DMEM, 2 mM glutamine prior
to adding TGF-b1 at 5 ng/ml or Activin-A at 30 ng/ml. Cells
were induced for 24 hours then lysed with 250 ml siGlow Lysis
Buffer (Promega) according to manufacturer’s procedures. Trans-
fections utilizing the constitutively active receptors were incubated
for 48 hours prior to lysis as above. 50 ml or 100 ml of lysate was
assayed with 100 ml Bright-Glow Luciferase Assay Reagent
(Promega). Transfection efficiency was normalized to b-galactosi-
dase levels by assaying 10 ml lysate to 100 ml Beta-Glo Assay
Reagent (Promega). Relative Luciferase units were obtained by
dividing the luciferase activity levels by the b-galactosidase levels.
Experiments were repeated at least twice and yielded essentially
the same results.
We used P19 cells to test specificity of TGFb induction of Bptf
protein levels. P19 cells were grown in 10% FBS, DMEM, 2 mM
glutamine, penicillin and streptomycin. Ligands were added at the
following concentrations; TGFb1 (R&D Systems) at 5 ng/ml,
FGF4 (R&D Systems) and heparin at 25 ng/ml and 1 ug/ml
respectively, BMP4 (R&D Systems) at 10 ng/ml and Wnt3a or L
cell control conditioned medium at 1:1 with 10% FBS, DMEM,
2 mM glutamine, penicillin and streptomycin. Cells were
incubated overnight and harvested for protein with TriReagent
reagent (Sigma) according to manufacturers procedures. Bptf
Western blotting was performed as described above.
Embryoid bodies were cultured as follows. ES cells were treated
with trypsin briefly to retain cells in medium sized clumps. Cells
were then centrifuged at low speed and resuspended in ESC
Growth Medium without LIF and cultured in bacteriological
grade petri dishes. ESC Growth Medium without LIF was
changed every day for 9 days with minimal disturbance to the
embryoid bodies. Samples were taken at specified time points
using TriReagent according to manufactures standard protocol or
fixed in 10% NBF for histology.
Knockout of Bptf in MEFs was accomplished by infecting litter
mate wild type and conditional Bptf (-/Floxed genotype) MEF lines
with an adenovirus expressing CMV-Cre. Infection was per-
formed in 6 well plates at sub-confluence (2610
5 cells) with 1 ml
growth media containing 45 ml Adenovirus @ 1610
10 PFU/ml.
Cells were grown for two days in the presence of virus. Following
infection cells were divided into 5 wells of a 6 well plate. Cell
numbers were recorded every 24 hours with changes in media
occurring every 48 hours. A sample of cells was removed at day 4
for Western analysis of Bptf protein levels. Experiment was
repeated with two wild type and conditional knockout MEF lines
from littermate embryos.
Chromatin Immuno Precipitation (ChIP)
ES cells were maintained on mitomycin C treated MEFs in ESC
Growth Media (15% FCS (ES Cell grade, Invitrogen), DMEM,
essential amino acids, 10 mM mercapto-ethanol, 2 mM glutamine,
100 U/ml LIF (Chemicon International), penicillin and strepto-
mycin). Culture techniques used were described previously [66].
Lines were passaged 3 times onto gelatinized plates to remove
MEFs prior to experiments.
Activin-A stimulation of ES cells was performed as follows. ES
cell lines were started on gelatinized plates in ESC Growth Media.
Cultures were then grown for 2 days in ESC Growth Media
without LIF. On the third day, cells were cultured in low serum
ESC Growth Media without LIF (same as ESC Growth Media
except 0.1% FCS is used instead of 15% FCS) in the presence or
absence of 30 ng/ml activin-A (R & D Systems) overnight.
Following activin-A induction cells were washed with PBS and
fixed in 2 mM EGS (Pierce) in 25% DMSO/75% PBS for 30 min
followed by 1% PFA in PBS for 30 min. For histone ChIP, cells
were fixed in 1% PFA in PBS for 15 min. Following fixation cells
were washed 3X in PBS and removed from the tissue culture dish
with a cell scraper. Cell pellets were then frozen at 280uC. The
following day the pellets were thawed and processed using the
ChIP procedure published by Upstate biologicals. Antibodies used
for pulldown were ChIP grade SNF2H/L (Abcam), H3 3me-K4,
H3 3me-K27 (Upstate) and pan H3 (Abcam).
Quantitation of pulldown was performed by real time PCR
using 26DyNAmo syprogreen qPCR kit (New England Biolabs)
according to manufacturers procedures. Briefly, reactions were
composed of 5 ml 1.2 mM forward and reverse primers, 5 ml
diluted cDNA template and 10 ml2 6qPCR mix (see Table S3 for
primer sequences). Reactions were heated for 10 min at 94uC,
then cycled for 40 cycles at 20 sec at 94uC, 20 sec at 60uC, 30 sec
at 72uC. After each cycle the sample was heated to 78uC for 10 sec
prior to reading sample fluorescence. Pulldowns were quantified as
a percentage of input using a dilution series as a standard curve.
Histone modification pulldowns are expressed as enrichment
relative to histone H3 occupancy under +activin-A conditions.
SNF2H/L pulldowns were first normalized to signal at Gapdh and
are expressed as the enrichment during +activin-A relative to
2activin-A conditions.
QPCR
RT reactions were performed on RNA extracted from ES cells,
embryoid bodies or P19 cells using TriReagent according to
manufacturer’s procedures. 5 mg of total RNA was reverse
transcribed with Superscript II using oligo dT priming according
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diluted 5–10 fold and used in a template for PCR.
Real time PCR was performed using 26DyNAmo syprogreen
qPCR kit (New England Biolabs) according to manufacturers
procedures. Briefly, reactions were composed of 5 ml 1.2 mM
forward and reverse primers, 5 ml diluted cDNA template and
10 ml2 6 qPCR mix (see Table S3 for primer sequences).
Reactions were heated for 10 min at 94uC, then cycled for 35
cycles at 20 sec at 94uC, 20 sec at 60uCo r5 2 uC, 30 sec at 72uC.
After each cycle the sample was heated to 78uC for 10 sec prior to
reading sample fluorescence. Reactions were done in triplicate.
DDCt method was used to quantify the relative levels of expression
to the Gapdh or b-actin house keeping genes. Expression levels were
then normalized to un-induced cells control cells.
QPCR was performed on E7.5 embryo cDNA as follows. Briefly,
reactionswerecomposed of5 ml1. 2mMfo rw ar da ndre ve rs ep ri me r
pair, 5 ml diluted cDNA template and 10 ml2 6 qPCR mix (see
TableS3forprimersequences).Reactionswere heated for10 minat
94uC, then cycled at 20 sec at 94uC, 20 sec at 60uC, and 30 sec at
72uC. The number of cycles to maintain linearity was determined
using the real time analysis software. PCR reactions within the linear
range were resolved using native PAGE.
Microarray
For microarray experiments we used one wildtype and two
independent Bptf mutant cell lines in 3 culture conditions (LIF+,
LIF2, and RA+). Experiments were carried out with 3 biological
replications. At the day 3, Triazole (1 ml/well; Invitrogen, USA)
was added to the well and total RNAs were extracted using Phase
lock gel columns (Eppendorf/Brinkman) according to the
manufacturer’s protocol. Total RNAs were precipitated with
isopropanol, washed with 70% ethanol, and dissolved in DEPC-
treated H2O. 2.5 g of total RNA samples were labeled with Cy3-
CTP using a Low RNA Input Fluorescent Linear Amplification
Kit (Agilent, USA). A reference target (Cy5-CTP-labeled) was
prepared from the Universal Mouse Reference RNA (Stratagene,
USA). Labeled targets were purified using an RNeasy Mini Kit
(Qiagen, USA) according to the Agilent’s protocol, quantified by a
NanoDrop scanning spectrophotometer (NanoDrop Technologies,
USA), and hybridized to the NIA Mouse 44K Microarray v2.2
(whole genome 60-mer oligo; manufactured by Agilent Technol-
ogies, #014117) [68]. Transcript copy number estimation using a
mouse whole-genome oligonucleotide microarray according to the
Agilent protocol (G4140-90030; Agilent 60-mer oligo microarray
processing protocol - SSC Wash, v1.0). All hybridizations were
carried out in the two color protocol by combining one Cy3-CTP-
labeled experimental target and Cy5-CTP-labeled reference
target. Microarrays were scanned on an Agilent DNA Microarray
Scanner, using standard settings, including automatic PMT
adjustment.
Differential gene expressions in various cell lines in the standard
culture condition were analyzed using the NIA Array Analysis
software (http://lgsun.grc.nia.nih.gov/ANOVA/) which imple-
ments ANOVA statistics with two additional methods to reduce
the number of false positives: (1) small error variances were
replaced with the average error variance estimated from 500 genes
with similar signal intensity, and (2) false discovery rates
(FDR,0.05) were used to select genes with differential expression,
instead of p-values [69]. The FDR method accounts for the effect
of multiple hypotheses testing.
Gene Ontology analysis and clustering was accomplished using
DAVID (http://david.abcc.ncifcrf.gov/) and the NIA Mouse
Gene Index (http://lgsun.grc.nia.nih.gov/geneindex/mm8) using
default settings [70].
GST Pulldowns
In vitro GST pulldown assays were performed in 50 ml volumes
in binding buffer (25 mM Hepes pH 7.4, 100 mM NaCl, 0.5 mM
MgCl2, 0.01% NP40), ,10 mg GST protein fusion bound to a
glutathione Sepharose support, 100 ng human NURF complex.
Proteins were allowed to bind for 1 hour at 4uC with occasional
mixing. The beads were washed with 500 ml binding buffer three
times at 4uC and re-suspended in a final volume of 30 ml.
NURF and CBP pulldowns from ES Cell extracts were
preformed essentially as described above from 500 mM KCl
nuclei extractions made as previously described [71]. The extract
was diluted 1:3 with 25 mM Hepes pH 7.4, 0.5 mM MgCl2,
0.01% NP40 with protease inhibitors (Roche) prior to binding to
resin bound GST-Smads. The beads were washed with 500 ml
binding buffer three times at 4uC and re-suspended in a final
volume of 30 ml. Proteins were eluted from the beads by adding
5 ml6 6 SDS sample buffer and incubating at 37uC for 30 min.
Proteins were resolved on 4% or 8% polyacrylamide gels and
transferred to PVDF (Biorad) and prepared for Western blotting as
described above.
Supporting Information
Figure S1 Bptf is the homolog of NURF 301. (A) Mouse Bptf
is highly homologous to Drosophila NURF301. Major functional
domains are conserved between mammals and flies, including
nucleosome and transcription factor binding sites, strongly
suggesting that Bptf is the homolog of the largest subunit of the
Drosophila NURF complex, NURF301. (B) Bptf is predominantly
nuclear in cultured P19 cells. siRNA targeting of Bptf results in
decreased Bptf signal by Western analysis and a reduction of
nuclear fluorescence by anti-Bptf immuno fluorescence in P19
cells. (C) Western analysis of adult brain, testis, spleen, and
embryonic stem cells reveals two migrating species, Bptf-H and
Bptf-L. (D) Western analysis of total protein extracts from adult
tissues using the affinity purified anti-Bptf antisera identifies a
single band of high molecular weight predominately found in
testis, spleen, and brain. In addition to full length Bptf, we identify
a single ˜100 kDa protein which reacts with the antibody
exclusively in the adult brain. This protein is identical in size to
the previously reported Bptf splice variant FAC1 (Bowser R,
Giambrone A, Daves P (1995) Dev Neuroscience 17: 20–37.). (E)
A similar western analysis of protein extracts from total embryo
proteins identifies high Bptf expression throughout development.
The ,100 kDa cross-reacting band was only found in the adult
brain loading standard and not during development.
Found at: doi:10.1371/journal.pgen.1000241.s001 (1.28 MB TIF)
Figure S2 Generation of conditional and gene trap alleles of
Bptf. (A) Intron-exon map of mouse Bptf showing alternatively
spliced exons and the position of the Bptf
XG023 trapping vector and
Bptf
DExon2 floxed exon. (B) Diagram of Bptf and Bptf
XG023 alleles
showing tandem trapping vector insertion site between exons 15
and 16. Restriction enzyme sites and positions of Southern blotting
probes used for the characterization of Bptf
XG023 are shown as
external probe A and internal probe B. Positions of primers used in
multiplex PCR genotyping are designated A, B, and C with A and
B complementing genomic sequence spanning the trapping vector
insertion site and C the trapping vector. (C) A Southern blot using
probe A showing diagnostic restriction enzyme sites confirming the
insertion of the trapping vector into Bptf. (D) A Southern blot using
Bgl II and probe B showing two bands characteristic of multiple
integration events by the trapping vector. Upper band contains
sequences external and lower band internal to the trapping vector.
(E) A Southern blot of genomic DNA digested with Nsi I, resolved
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heterozygous mice with an approximate size of 30 Kb, suggesting
3 to 4 trapping vector integration events. (F) Results from
multiplex PCR analysis of wild type (+/+), heterozygous (+/-),
and homozygous (2/2) Bptf
XG023 E7.5 embryos using primers A,
B, and C. The wild type and mutant alleles are identified by a
325 bp and 500 bp product, respectively. (G) Diagram of Bptf,
Bptf
Floxed-Neo, Bptf
Floxed, and Bptf
DExon2 alleles showing the configu-
ration of the integrated targeting vector and its Cre and Flp
reaction products. Restriction enzyme sites and positions of
Southern blotting probes used for the characterization of Bptf
DExon2
are shown as external probe 29–31 and internal probes 20.2–20.7,
exon2 and 25–26. Positions of primers used in multiplex PCR
genotyping are designated A, B, C, E, and F. (H) A Southern blot
of heterozygous Bptf
Floxed-Neo, Bptf
Floxed, and Bptf
DExon2 alleles using
Sca I and probe 25–26 showing diagnostic restriction enzyme sites
confirming the insertion of the targeting vector into Bptf and the
products of Cre and Flp recombination. (I) A Southern blot of the
same mice as in (H) using Eco RI and probe 25–26. (J) A Southern
blot of the same mice as in (H) using EcoRI and probe 29–31. (K)
A Southern blot of same mice as in (H) using Eco RI and probe
20.2–20.7. (L) A Southern blot of same mice as in (H) using Kpn I
and probe 20.2–20.7. (M) Results from multiplex PCR analysis of
wild type Bptf and heterozygous Bptf
Floxed-Neo, Bptf
Floxed, and
Bptf
DExon2 alleles using primers E, F, and C. The multiplex PCR
strategy yields band sizes of Bptf=375 bp, Bptf
Floxed = 475 bp, and
Bptf
DExon2=650 bp. (N) Results from multiplex PCR analysis of
wild type Bptf and heterozygous Bptf
Floxed-Neo, Bptf
Floxed, and
Bptf
DExon2 alleles using primers A, B, and C. The multiplex PCR
strategy yields band sizes of Bptf=250 bp, Bptf
Floxed-Neo, Bptf
Floxed =
325 bp, and Bptf
DExon2=500 bp.
Found at: doi:10.1371/journal.pgen.1000241.s002 (1.89 MB TIF)
Figure S3 Molecular characterization of Bptf
XG023 allele. (A)
PCR amplification and sequencing of the upstream junction
between the trapping vector and the mouse genome confirm the
exact position of the trapping vector to be between exon 15 and 16
of Bptf. (B) RT-PCR results from E7.5 embryos show reduced
expression of 39-RNA sequences and severely reduced exon 15–16
splicing, confirming efficient trapping of Bptf by the trapping
vector insertion. (C) DNA sequence of a 59-RACE amplicon of the
Bptf
XG023 allele from testis shows an in-frame fusion between exon
15 of Bptf and b-Geo from the trapping vector. (D) Northern
analysis of RNA from wild type and heterozygous Bptf
XG023
disruption mice show predominant transcripts in testis, lungs,
spleen, and brain using a probe specific for Bptf mRNA. The Bptf-
b-Geo fusion RNA has the same expression patterns as the wild
type allele, suggesting that the trapping vector does not interfere
with Bptf regulation at the level of transcription.
Found at: doi:10.1371/journal.pgen.1000241.s003 (1.34 MB TIF)
Figure S4 Molecular characterization of Bptf
DExon2 allele. (A)
RT-PCR results from E7.5 embryos show slightly reduced
expression of 39-RNA sequences of Bptf
DExon2 at the RNA level.
(B) RT-PCR results from E7.5 embryos show deletion of exon 2
RNA sequences from Bptf
DExon2 transcripts. Primers used were
complementary to exons 1 and 8. (C) RT-PCR products from
Bptf
DExon2 transcripts in (B) were sequenced to identify out of frame
splicing events, strongly suggesting that the exon 2 deletion results
in efficient knockout of the Bptf protein.
Found at: doi:10.1371/journal.pgen.1000241.s004 (0.64 MB TIF)
Figure S5 Bptf
DExon2 and Bptf
XG023 alleles are genetically
equivalent. (A) Wild type (+/+), heterozygous (+/2), and
homozygous (2/2) Bptf
DExon2 embryos at E5.5, E6.5, and E7.5
were removed from their decedua and genotyped using a PCR-
based method. Identical to the Bptf
XG023 allele, reduced growth
rates are evident in the homozygous Bptf
DExon2 embryos as early as
E5.5. Mutant embryos from both lines maintained the gross
morphology of E5.5 embryos at E6.5 and E7.5 with an overall
increase in size. (B) Heterozygous Bptf
XG023 and Bptf
DExon2 mice
were intercrossed, and wild type, Bptf
DExon2 heterozygous, Bptf
XG023
heterozygous, and Bptf
XG023 / Bptf
DExon2 trans-heterozygous
embryos were dissected from their decidua at E6.5, and genotypes
were confirmed by PCR. Trans-heterozygous embryos phenocopy
homozygous Bptf
XG023 or Bptf
DExon2 embryos, suggesting that the
two alleles have an equivalent phenotype.
Found at: doi:10.1371/journal.pgen.1000241.s005 (3.04 MB TIF)
Figure S6 Bptf mutants do not have significant growth defects
prior to implantation. Wild type (+/+), heterozygous (+/2), and
homozygous (2/2) Bptf
XG023 or Bptf
DExon2 E3.5 blastocysts and 5-
day blastocyst outgrowths did not reveal any significant morpho-
logical or growth differences in trophoblast or the inner cell mass.
Found at: doi:10.1371/journal.pgen.1000241.s006 (1.36 MB TIF)
Figure S7 Bptf mutants have reduced cellular proliferation.
Percent phosphorylated histone H3 positive cells from total cells of
the control and mutant embryos were quantified to show reduced
cellular proliferation of Bptf mutant embryos at E5.5, E6.5, and
E7.5.
Found at: doi:10.1371/journal.pgen.1000241.s007 (0.15 MB TIF)
Figure S8 Bptf
XG023 is widely expressed in the embryo
proper. (A–D) Wild type and heterozygous embryos were stained
in whole mount for b-galactosidase activity at E5.5 and E6.5.
Bptf
XG023 expression is present in E5.5 and E6.5 embryos in
embryonic but not extra-embryonic tissues. (E–G) Wild type and
heterozygous E7.5 embryos were stained in whole mount for b-
galactosidase activity. Bptf
XG023 expression is present at E7.5
embryos in embryonic but not extra-embryonic tissues. (a9) Cross
section of the E7.5 heterozygous embryo shows expression
exclusive to the embryonic ectoderm and little to no expression
in the visceral endoderm. (b9) Cross-section of the E7.5
heterozygous embryo shows expression primarily in the embryonic
ectoderm, reduced expression in the mesoderm, with little to no
expression in the visceral endoderm. Abbreviations: ve, visceral
endoderm; ee, embryonic ectoderm; m, mesoderm.
Found at: doi:10.1371/journal.pgen.1000241.s008 (0.34 MB TIF)
Figure S9 Bptf
XG023 expression during embryonic develop-
ment. (A–E) Wild type (+/+) and heterozygous (+/2) Bptf
XG023
embryos were dissected from their decidua and stained in whole
mount for b-galactosidase activity. Staining is seen predominantly
in the embryonic tissues at E7.5 (A) and E8.5 (B). At later stages of
development, expression is ubiquitous in the embryo (C–E). (F)
Sagittal section of E10.5 embryo stained for b-galactosidase
activity reveals the extent of Bptf
XG023 expression. Expression was
observed in many tissues originating from mesoderm (notochord,
myocoele, somites), endoderm (lung bud), and ectoderm (fore-
brain, midbrain, hindbrain, and neural tube). Scale Bar=400 mm.
Found at: doi:10.1371/journal.pgen.1000241.s009 (4.01 MB TIF)
Figure S10 An analysis of Nodal expression at E5.5 shows Bptf
mutants express Nodal at levels comparable to wild type. (A) Bptf
mutants express Nodal in the visceral endoderm at E5.5 at
comparable levels to the wild type control. (B) Bptf mutants express
delocalized Nodal at E6.5.
Found at: doi:10.1371/journal.pgen.1000241.s010 (1.94 MB TIF)
Figure S11 Bptf mutants cannot establish an anterior–posterior
axis. (A,B) Whole mount in situ RNA hybridization analysis of
wild type and mutant E6.5 and E7.5 embryos for Cer1, Nodal,
Bptf and Development of Mouse Embryo
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Mash2, Bmp4, Erbb2, and Fgfr2 expression. An analysis on wild type
and Bptf mutant E6.5 embryos for anterior visceral endoderm
(AVE) markers Cer1, Lefty1, and Hex1 show that mutants do not
develop an AVE. Bptf mutants show comparable but delocalized
Nodal and Cripto expression at E6.5, further suggesting a defect in
the development of the AVE. Embryos showed reduced expression
of the embryonic ectoderm marker Otx2 and Hesx1 in mutants
compared to wild type controls, suggesting defects in the
embryonic ectoderm. Primitive streak markers Lhx1, T, Gsc, Fgf8,
and Foxa2 also show a significant reduction in expression in
mutant at E6.5 compared to wild type. The extra-embryonic
markers Bmp4, Erbb2, Fgfr2, and Mash2 are not dramatically
affected in mutant when compared to wild type embryos at E6.5.
The cell cycle regulatory gene Junb was found to be over expressed
in mutant relative to wild type controls at E6.5. Analysis of E7.5
embryos confirms that Bptf mutants do not establish an anterior–
posterior axis. Lhx1 is not significantly expressed at E7.5 in mutant
compared to wild type, suggesting that primitive streak does not
form. Expression of mesoderm markers T and Fgf8 is diffuse in
mutant embryos compared to wild type at E7.5, suggesting that
the embryo proper becomes unorganized mesoderm-like tissue.
The extra-embryonic markers Bmp4 and Mash2 maintain extra-
embryonic expression in E7.5 mutant embryos. Angiogenesis
markers Vegf and Flk1 show little expression in the extra embryonic
portion of the embryo as compared to wild type controls.
However, expression is not associated with an allantois, which is
severely underdeveloped in Bptf mutant embryos. Bptf expression is
largely confined to the embryonic tissues at E7.5.
Found at: doi:10.1371/journal.pgen.1000241.s011 (6.17 MB TIF)
Figure S12 Construction of Bptf mutant embryonic stem (ES)
cell lines. (A) Retargeting and subsequent transient Cre expres-
sion generated conditional heterozygous (not shown), heterozygous
(+/2), conditional homozygous (Floxed-Neo/-), and homozygous
(2/2) mutant Bptf mouse ES cell clones. Genotypes were
confirmed by Southern analysis using an Eco R1 digest and
hybridization with Probe 20.2–20.7. (B) Northern analysis of Bptf-
mutant ES cell clones using a probe to the 39-end of the gene
shows reduced Bptf transcript levels. (C) RT-PCR analysis of wild
type (+/+) and homozygous mutant (2/2) RNA confirms the
complete deletion of exon 2 from Bptf transcripts in homozygous
mutant clones. Sequence from Bptf mutant PCR products shows
the Bptf transcript contains exon 1–3 and 1–4 out of frame splice
events as seen in Figure S4C (data not shown). (D) Western
analysis of Bptf wild type, heterozygous, conditional heterozygous,
and mutant ES cells. Heterozygosity at Bptf results in reduced Bptf
protein levels, raising the possibility of haploinsufficiency pheno-
types. Homozygous Bptf ES cells mutants do not show Bptf
protein, demonstrating that Bptf
DExon2 is likely to be a null allele.
FAC1 expression was not found in ES cells.
Found at: doi:10.1371/journal.pgen.1000241.s012 (0.71 MB TIF)
Figure S13 Conditional deletion of Bptf in mouse embryonic
fibroblasts (MEF) with adenovirus expressing Cre recombinase.
Conditional Bptf mutant (2/Floxed) and control (+/+) MEF lines
were infected with an adenovirus expressing the Cre recombinase.
Infected (+Cre) and mock infected (2Cre) cells were passaged
once to deplete the cellular stores of the Bptf protein. Following
growth for 4 days, cells were harvested for total protein. Bptf
protein was detected by Western using ponceau S staining as a
loading control.
Found at: doi:10.1371/journal.pgen.1000241.s013 (0.57 MB TIF)
Figure S14 Bptf mutant embryonic stem (ES) and mouse
embryonic fibroblast (MEF) cell lines show slight growth
defects. (A) The doubling time of wild type and mutant ES cells
was investigated. We observed that Bptf mutants but not
conditional heterozygous or heterozygous ES cells showed reduced
growth rates relative to wild type (+/+) cell lines. A cell cycle
analysis of slower growing Bptf knockout ES cell lines shows that
they have a slight G1 to S phase delay. (B) The doubling time of
wild type and mutant MEF lines was investigated. We observed
that Bptf-depleted MEF lines showed slightly reduced growth rates
relative to control lines.
Found at: doi:10.1371/journal.pgen.1000241.s014 (0.24 MB TIF)
Figure S15 Bptf mutant mouse embryonic stem (ES) cells do not
differentiate as embryoid bodies, are not apoptotic, and proliferate
normally. (A) Day 9 embryoid bodies were sectioned and stained
for gross analysis with hematoxylin and eosin (H&E), the
proliferation markers PCNA and phosphorylated histone H3,
and apoptosis by TUNEL. Bptf-mutant (2/2) embryoid bodies
contained few differentiated and TUNEL positive apoptotic cells
compared to wild type (+/+) controls. TUNEL negative Bptf
mutant (2/2) and wild type (+/+) cells have similar staining for
proliferation markers PCNA and phosphorylated histone H3. (B)
Microscopy of wild type and Bptf mutant ES cells during a 9-day
embryoid body differentiation time course. Bptf mutant ES cells
did not develop the size and cystic structures of the wild type
controls. (C) Wild type but not mutant day 9 embryoid bodies
develop a prominent layer of endoderm on the exterior surface. In
place of endoderm Bptf knockout, embryoid bodies develop a thin
epithelial cell layer.
Found at: doi:10.1371/journal.pgen.1000241.s015 (3.46 MB TIF)
Figure S16 Bptf-mutant embryoid bodies show little to modest
deregulation of cell cycle and pluripotency markers. Gene
expression was monitored from total RNA during a 9-day
embryoid body differentiation time course. RT-PCR analysis for
cell cycle markers (A), pluripotency markers (B).
Found at: doi:10.1371/journal.pgen.1000241.s016 (0.93 MB TIF)
Figure S17 Transcription and differentiation defects in
Bptf
DExon2 knockout embryonic stem (ES) cells are rescued by
reintroduction of Bptf
Floxed-Neo. (A) Bptf
DExon2/Bptf
DExon2 ES cell
lines were retargeted with the Bptf
Floxed-Neo targeting vector to
generate Bptf
DExon2/Bptf
Floxed-Neo rescue lines. Recombination of the
targeting vector at Bptf
DExon2 was confirmed by Southern blotting
Sca I digested DNA and probing with Probe 25–26. (B) A Western
analysis of total protein from parental Bptf
DExon2/Bptf
Floxed-Neo,
Bptf
DExon2/Bptf
DExon2, and Bptf
DExon2/Bptf
Floxed-Neo rescue lines show
reintroduction of the Bptf protein. (C) Expression analysis of
mesoderm markers T, Gsc, and endoderm markers Sox17, Cer in a
Bptf
DExon2/Bptf
Floxed-Neo rescue ES cell line during a 9-day embryoid
body differentiation time course. Reintroduction of Bptf
Floxed-Neo
rescued the induction of mesoderm and endoderm markers during
embryoid differentiation.
Found at: doi:10.1371/journal.pgen.1000241.s017 (0.90 MB TIF)
Figure S18 Gene ontology clustering analysis of Bptf-dependent
genes by condition. The entire array dataset from each condition
was analyzed for statistically significant ontology clusters using
DAVID analysis software. Genes that were repressed in expression
cluster to highly similar ontology groups and include those
involved in ‘‘development’’, ‘‘transcription factor activity’’, and
‘‘morphogenesis’’. Activated gene clusters are highly dependent on
condition and include ‘‘antigen processing’’, ‘‘peptidase inhibi-
tors’’, and ‘‘cytoskeletal components’’.
Found at: doi:10.1371/journal.pgen.1000241.s018 (0.88 MB TIF)
Figure S19 Bptf negatively regulates many homeobox transcrip-
tion factors. (A) Genes containing a homeobox but not the helix
Bptf and Development of Mouse Embryo
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up-regulated gene sets. (B) Expression levels of homeobox
transcription factor gene clusters displayed as a heat map. Almost
the entire a, b, and c clusters are deregulated, suggesting that Bptf
plays an important function in regulating clusters of homeobox
domain–containing transcription factors.
Found at: doi:10.1371/journal.pgen.1000241.s019 (0.35 MB TIF)
Figure S20 Bptf preferentially potentates dynamically regulated
genes with bivalent promoters. (A) Genes whose transcription
activates, represses, or is unchanged upon LIF- conditions or the
addition of retinoic acid (RA) were analyzed for Bptf dependence.
Knockout of Bptf results in predominantly reduced activation
(repression of activated genes with Bptf knockout) or reduced
repression (activation of repressed genes with Bptf knockout) of
dynamically regulated genes. (B) Bptf preferentially regulates
promoters with bivalent histone modifications. The methylation
state expressed as a percentage of all promoters from undifferen-
tiated mouse ES cells. Data was retrieved from Bernstein et. al.
(2006) Cell 125:315–326. Bptf-dependent genes from the micro-
array dataset were grouped based on the promoter’s methylation
state. From this analysis, Bptf-dependent genes are predominantly
enriched for bivalent histone H3 3me-K27, histone H3 3me-K4
over single modified or unmodified promoters. (C) The magnitude
of deregulation was compared between activated and repressed
genes for each condition of Bptf dependence. A breakdown of gene
classes by condition shows that the transcriptome is repressed
under LIF+ and RA growth conditions and activated under LIF-.
(D) The modifications on bulk histones in Bptf mutant embryonic
stem (ES) cells are consistent with a transcriptionally repressed
chromatin state. Bulk histones were prepared from wild type (+/+)
and two Bptf mutant (2/2) ES cell lines grown in LIF+ growth
media. Total protein extracts were then probed for histone
modifications by Western blotting. Bptf knockout ES cells have an
increase of the repressive H3 3me-K9 and H3 3me-K27 and a
decrease of the activating marks H3 ac-K18 and H4 ac-K5.
Interestingly, knockout ES cells have an increase in levels of c-
H2AX, a mark correlated with DNA damage, and H3 3me-K36,
a mark of transcription elongation.
Found at: doi:10.1371/journal.pgen.1000241.s020 (0.97 MB TIF)
Figure S21 Bptf-dependent genes are frequently located in
clusters. The chromosome position for each Bptf-dependent
gene was identified, and statistically significant gene clusters are
shown with a letter designation. Clusters include genes with similar
regulation and imprinted clusters.
Found at: doi:10.1371/journal.pgen.1000241.s021 (1.80 MB TIF)
Figure S22 Western analysis of Bptf, CBP/p300 knockdown
and Smad2 activation during TGF-b1 and activin-A stimula-
tion. (A) Wild type and Bptf mutant embryonic stem (ES) cells
were induced with activin-A for 24 hours. Western analysis shows
up-regulation of Bptf protein levels and the phosphorylation of
Smad2 in wild type and Bptf mutant ES cells with the addition of
activin-A. (B) TGF-b1 selectively increases protein levels of Bptf in
P19 cells. P19 cells were treated with TGF-b1, BMP4, Wnt3a-
conditioned media, and FGF4+heparin for 24 hours. Following
induction, cells were harvested and analyzed for Bptf levels by
Western blotting. TGF-b1 increased and Wnt3a decreased Bptf
protein levels. (C) Wild type ES cells were subjected to siRNA
mediated knockdown of Bptf and CBP/p300, followed by
induction with activin-A. Western analysis shows siRNA mediated
knockdown of Bptf and CBP/p300 and phosphorylation of Smad2
with the addition of activin-A.
Found at: doi:10.1371/journal.pgen.1000241.s022 (1.28 MB TIF)
Figure S23 Bptf is necessary for Smad mediated gene transcrip-
tion of cell cycle regulators. RT-PCR analysis of Smad target
genes from activin-A–induced embryonic stem cells identifies Bptf-
dependent and -independent gene targets. The repression of p21
during stimulation with activin-A is dependent on Bptf.
Found at: doi:10.1371/journal.pgen.1000241.s023 (0.21 MB TIF)
Figure S24 Bptf is necessary for activation of Smad-responsive
promoter elements. (A) Knockdown of Bptf in P19 cells renders
Smad responsive Smad binding elements (SBE) unresponsive to
Smad activation via TGF-b. Luciferase activity was measured
from stimulated or unstimulated P19 cells transfected with Bptf or
mock siRNAs in addition to pGL3ti-(SBE)4 and LacZ transfection
control plasmid. (B) Knockdown of Bptf in P19 cells renders Smad
responsive ARE elements unresponsive to Smad activation via
activin-A. Luciferase activity was measured from stimulated or
unstimulated P19 cells transfected with Bptf or mock siRNAs in
addition to pA3-Luc, CMV-Fast2-myc, and LacZ transfection
control plasmid. (C) Co-transfection of HA-Smads 2,4 and
constitutively active TbRI results in increased activation of
luciferase reporter regulated by the SBE. (D) Knockdown of Bptf
in P19 cells renders SBE Smad responsive elements unresponsive
to constitutively activated Smad transcription factors. Luciferase
activity was measured from P19 cells transfected with Bptf or mock
siRNAs and combinations of Smad transcription factors, consti-
tutively active type I receptor TbRI*, pGL3ti-(SBE)4, and a LacZ
transfection control plasmid. (E) Western analysis showing siRNA
mediated knockdown of Bptf in P19 cells during TGF-b1
induction. (F) Some TGF-b1-responsive gene targets in P19 cells
are Bptf-dependent. Bptf knockdown during TGF-b1 activation
significantly reduces the Smad mediated gene activation of Cer and
T. (G) Western analysis showing siRNA mediated knockdown of
BPTF in MCF10CA1 cells during TGF-b1 induction. (H) BPTF
knockdown during TGF-b1 activation significantly reduces the
Smad mediated gene activation of PAI-1 but not SMAD7.
Found at: doi:10.1371/journal.pgen.1000241.s024 (1.16 MB TIF)
Figure S25 Bptf-mutant embryos likely do not down regulate the
Smad signaling pathway indirectly. (A) RT-PCR analysis of E7.5
embryos shows normal expression of the BMP4 ligand, Smad 1,2
and 4 transcription factors, and receptors ALK3, Alk-IIB.
Expression of the TGFb-responsive gene JunB is significantly
increased in mutant embryos. (B) Results from quantitative RT-
PCR measurements of additional markers of early embryonic
development in E7.5 embryos. Expression has been normalized to
GAPDH levels and is expressed as the ratio mutant/WT. (C) An
RT-PCR analysis of wild type and Bptf-mutant embryoid body
differentiation time course for Smad transcription factors, Bptf, and
the Smad responsive gene Serpine1.
Found at: doi:10.1371/journal.pgen.1000241.s025 (0.64 MB TIF)
Table S1 Disruption of Bptf results in early embryonic
lethality. (A) Wild type (+/+) and heterozygous (+/2) Bptf
XG023
males and females were mated in reciprocal crosses and all
progeny were genotyped by Southern blotting or PCR. Homozy-
gous (2/2) Bptf
XG023 embryos were not viable after E7.5 to E8.5,
showing that mutations in Bptf are early embryonic lethal.
Curiously, more reabsorptions were observed during the dissec-
tions than could be accounted for from the death of the
homozygous Bptf
XG023 embryos. To investigate if the origin of
the increased lethality was caused by a parental Bptf
XG023
heterozygous contribution, we crossed heterozygous to wild type
males and females in combinations and examined all embryos
from E10.5 to E18.5. From these experiments, we observed an
increased number of reabsorptions when the mother was
heterozygous compared to the wild type controls (Table S1A, b–
Bptf and Development of Mouse Embryo
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embryos, as they were found in the expected 1:1 ratio to wild type.
These data suggested that Bptf
XG023 conferred a maternal effect on
embryo survival. (B) As in (A), heterozygous (+/2) Bptf
DExon2 males
and females were intercrossed and all progeny were genotyped by
Southern blotting or PCR. As with Bptf
XG023, homozygous (2/2)
Bptf
DExon2 embryos were not viable after E7.5 to E8.5.
Found at: doi:10.1371/journal.pgen.1000241.s026 (0.33 MB TIF)
Table S2 Bptf mutants show highly similar phenotypes to Smad
and Nodal mutants. Phenotypes of Bptf mutants during blasto-
cyst outgrowth and the establishment of the DVE, AVE, and
primitive streak were compared to phenotypes from mutations of
Smad2/4, Nodal, Wnt3/b-catenin, remodelers BRG1/SNF2H,
and essential genes. Bptf mutations closely resemble mutations in
Smad and Nodal pathways.
Found at: doi:10.1371/journal.pgen.1000241.s027 (0.30 MB TIF)
Table S3 Primer and siRNA sequences used in study.
Sequences of all siRNA duplexes and primers used in this study
are shown in table format.
Found at: doi:10.1371/journal.pgen.1000241.s028 (1.47 MB TIF)
Dataset S1 Microarray and analysis datasets.
Found at: doi:10.1371/journal.pgen.1000241.s029 (21.56 MB
XLS)
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